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Pharmacogenetics of Chemotherapy-Induced Peripheral Neuropathy 
Katherina Cairene Chua 
 
ABSTRACT 
Anticancer therapies are commonly prescribed for breast cancer and other solid tumors. While 
cytotoxic agents are therapeutically efficacious in treatment of many cancers, they often lead to 
significant toxicities. One of the main non-hematological dose-limiting toxicities for cytotoxic 
chemotherapies is sensory peripheral neuropathy. Currently, there are no effective therapeutic 
strategies to prevent or treat chemotherapy-induced peripheral neuropathy (CIPN) due to the lack 
of understanding in the mechanisms underlying patient susceptibility. This dissertation presents a 
pharmacogenetic approach to aid in the identification of critical genetic networks that may 
explain the development of CIPN. With the use of genome-wide association studies conducted 
from clinical samples of breast cancer patients treated with microtubule-targeting agents, we 
highlighted the role of sphingosine lipid signaling in microtubule-targeting agent (MTA)-induced 
peripheral neuropathy (PN). Functional studies using human sensory neurons derived from 
induced pluripotent stem cells show that inhibiting such pathway attenuates paclitaxel-induced 
neuronal injury. Additional genes also involved in Rho GTPase signaling were further revealed 
from a next-generation exome sequencing study on patients treated with MTA chemotherapy. 
Future efforts are needed to explore how disruption in this signaling pathway develops on the 
molecular level and subsequently leads to manifestation of CIPN. While these studies have 
focused on revealing insights of the pathophysiology underlying CIPN, we also investigated the 
use of early patient-reported symptoms and genome-wide data for the prediction of dose-limiting 
neuropathy events. We show that early patient-reported outcomes can be used as a tool to predict 
	 vii	
risk for dose-limiting toxicity events. Future studies aimed at determining whether other types of 
genomic and clinical information may help improve such predictions. Together, the work 
presented herein provide novel insights to mechanisms underlying the development of CIPN in 
efforts to discover novel strategies for CIPN prevention and treatment. 
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CHAPTER 1:  Clinical and Mechanistic Features of Chemotherapy-Induced Peripheral 
Neuropathy 
 
Cytotoxic chemotherapeutic agents, or antineoplastic agents, are a class of drugs that target and 
eliminate rapidly dividing cells, and are clinically efficacious as first-line treatments for various 
cancers. However, clinical benefit of anticancer therapies can often be limited by serious adverse 
toxicities that significantly impact a patient’s quality of life during and after treatment. While 
incidence varies among therapeutic regimens, chemotherapy-induced peripheral neuropathy 
(CIPN) is a common dose-limiting toxicity generally experienced in 30-40% of patients 
undergoing treatment with certain single or combination anticancer therapies1. Common 
chemotherapeutics associated with CIPN include taxanes (e.g., paclitaxel and docetaxel), vinca 
alkaloids (e.g., vincristine and vinblastine), platinum agents (e.g., oxaliplatin and cisplatin), 
epothilones (i.e. ixabepilone), proteasome inhibitors (i.e. bortezomib) and others (e.g., eribulin 
and thalidomide)2. Treatments with taxanes and platinum agents have the highest reported rates 
of CIPN among these drug classes, ranging up to more than 85%3–5 . While much is known about 
these drug classes and their mechanisms of action, the mechanisms by which CIPN initiates, 
develops, and progresses are still inadequately understood, despite decades of research. As a 
result, there are also no currently effective strategies for its prevention or treatment.  
 
Clinical Characteristics and Diagnosis of CIPN 
Chemotherapy-induced nerve damage is experienced in a “glove and stocking” distribution, 
where longest axons and most distal nerves are first affected. CIPN presents predominantly as a 
sensory neuropathy, manifesting in the hands and feet; motor neuropathy is less common and 
when present typically develops subsequent to sensory neuropathy. Variability in patient 
experience of CIPN presents a challenge in characterizing the severity of the toxicity, and 
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symptoms can vary depending on the therapy; however, typical sensory neuropathic symptoms 
comprise of numbness and/or tingling, abnormal touch sensations, temperature-stimulated 
hypersensitivity, and/or burning/painful vibrations.5–7 Of note, oxaliplatin is known to 
specifically induce cold-stimulated pain and tingling in about 80% of patients8,9, a phenotype not 
observed with other neurotoxic chemotherapeutics. Neurological examination of patients with 
CIPN often shows loss of reflexes and reduced sensory perception to external touch and 
vibration2,5,10,11. Severe CIPN symptoms can significantly interfere with daily activities such as 
writing, dressing, or even walking, which give rise to secondary complications1. CIPN symptoms 
can persist for years1,7,12–14; these symptoms can even progress or “coast” even after treatment 
has ceased2,15, a commonly documented phenomenon with platinum-based therapies. In severe 
cases of CIPN, normal function may never completely return16,17. Survivors with chronic CIPN 
symptoms also bear significant post-treatment economic burden with higher healthcare costs and 
increased workloss burden7,18,19. 
 
Table 1.1 Reported incidence rates of CIPN and observed threshold cumulative doses for most 
common chemotherapy agents2–4,11,20–22 
Drug class Chemotherapy agent Reported onset 
cumulative dose 
(mg/m2) 
Incidence reported 
Platinum-based 
agents 
Cisplatin ≥ 300-600  49-100%  
Carboplatin ≥ 400-600 25%  
Oxaliplatin  ≥ 300-700 40-70%  
Vinca alkaloid Vincristine > 4-20 20-60% 
Taxanes Paclitaxel ≥ 800-1400 30-100% 
Nab-paclitaxel NR 10-51% 
Docetaxel > 400-600 6-10% 
Immunomodulatory 
agent 
Thalidomide 20 g (total) 25-75% 
Epothilone Ixabepilone > 40 15-71% 
Proteasome 
inhibitor 
Bortezomib 1-1.3 35-50% 
NR: not reported 
	 3	
 
The onset and severity of CIPN symptoms are drug-specific (Table 1.1) but generally 
dependent on the dosing frequency, route of delivery, and cumulative drug exposure2–4,11,20–22. 
Treatments with taxanes and platinum-based agents have been documented to induce acute 
neuropathic pain as early as the first cycle23,24, which is not typically observed with other 
chemotherapeutics. Clinical risk factors for developing CIPN include pre-existing neuropathy 
(e.g., diabetic neuropathy or inherited neuropathy), diabetic status, age, abnormal creatinine 
clearance, prior treatment with neurotoxic agents, and high-exposure dosing regimens1,4,25; 
however, these factors do not completely account for the interindividual variation in CIPN 
clinically observed6. Recent studies have aimed at identifying genetic risk factors, including 
single nucleotide polymorphisms (SNPs), to understand patient susceptibility and guide 
treatment decisions. While currently no genetic association has shown clinical utility to predict 
risk of CIPN, these efforts have discovered exciting insights into the pathophysiology of CIPN 
and are reviewed in a later section. 
A number of assessment tools are used for diagnosing, monitoring and describing the 
progression of CIPN, including common toxicity grading scales, neurophysiological tests, and 
patient reported surveys5,11,26. The traditional method used for evaluating CIPN is the National 
Cancer Institute – Common Terminology Criteria for Adverse Events (NCI-CTCAE) scale, 
where clinicians grade CIPN severity on a 1-5 scale (Table 1.2). Dose reductions, treatment 
delays, or cessation of therapy are considered when severe neuropathy is experienced, usually 
defined as grade 3 or higher events where sensory impairment interferes with activities of daily 
living26. Neurological quantitative sensory tests can be used to diagnose CIPN, and measure 
diminished neurological function characterized by reduced sensory nerve conduction velocities, 
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sensory nerve action potential amplitudes, and increased vibration thresholds27,28. However, 
these tests are only limited to diagnosis without any standard guidelines to implement the results 
into clinical practice, and have not shown consistent correlation to severity of CIPN10,29,30. 
Recently, there is increasing interest in utilization of patient reported outcomes (PRO) in clinical 
settings. In at least some studies, PRO shows clinical validity and reliability compared with NCI-
CTCAE reporting31–34; however, the development of PRO-based standard protocols is critical for 
application into clinical decisions. 
Table 1.2 Grading scale for NCI-CTCAE for peripheral sensory neuropathy 
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 
Asymptomatic; loss 
of deep tendon 
reflexes or 
paresthesia 
Moderate 
symptoms; limiting 
instrumental ADL 
Severe symptoms; 
limiting self care ADL 
Life-threatening 
consequences; 
urgent intervention 
indicated 
Death 
ADL: activity of daily living 
As the number of cancer survivors continues to increase, the importance of addressing 
CIPN to improve long-term quality of life has gained recognition. As a result, the 2014 
American Society of Clinical Oncology (ASCO) clinical practice guideline6 reviewed previously 
investigated prevention and treatment strategies against CIPN from clinical trial results, 
including use of chemoprotectants (amifostine, recombinant human leukemia inhibitory factor, 
nimodipine), anticonvulsants (carbamazepine, oxycarbazepine, lamotrigine, gabapentin), 
antidepressants (nortriptyline, amitriptyline, venlafaxine, ketamine, duloxetine), and various 
supplements (calcium and magnesium, vitamin E, glutathione, acetylcysteine, acetyl-L-carnitine, 
glutamate/glutamine, omega-3 fatty acids, goshajinkigan, retinoic acid, diethyldithiocarbamate). 
Despite all these efforts to identify therapeutic approaches to combat CIPN, there are currently 
no clinical recommendations for prevention and only a moderate recommendation for the use of 
duloxetine in the treatment of existing CIPN6. The most effective method for preventing CIPN is 
dose reduction and/or therapy discontinuation, which influences the decision to balance 
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maximum chemotherapeutic benefit that may lead to survival and long-term well-being after 
completion of therapy.  The development of clinically effective therapies to prevent and/or treat 
CIPN is limited by our current understanding of the molecular basis for CIPN. Although clinical 
presentation of CIPN is relatively consistent among chemotherapies, genetic and functional 
studies collectively suggest that the predisposition and mechanisms of this neurotoxicity may be 
chemotherapy-specific.  
 
Pathogenesis of CIPN 
Decades of research with in vitro and in vivo models of CIPN have revealed some key 
morphological changes in the affected nerves that are now hallmarks of CIPN5,35–43, including 
the loss of intraepidermal nerve fiber endings, preferential sensory axonal degeneration, 
mitochondrial vacuolation, and varying degrees of demyelination. Although the presence, 
severity, and mechanism of these traits vary with drug treatment, loss of nerve innervation is the 
most consistent morphological effect observed from patient skin biopsies44–47 and in vivo models 
of CIPN35,36,48–50. This “dying back” phenotype occurs when epidermal nerve fibers on the 
outermost layer of the skin are depleted and/or fragmented51 (Figure 1.1), and is mostly 
attributed to drug-specific damage inflicted on the dorsal root ganglion (DRG) neurons.  
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Figure 1.1 Diagram of innervation of skin in healthy individuals (A) and in those with 
neuropathy (B). (Adapted from Landowskia et al.51) 
 
Since the majority of the mechanistic studies that characterize CIPN and our clinical 
pharmacogenomic studies are derived from studying neuropathy induced by microtubule-
targeting agents (taxanes, vinca alkaloids, eribulin, epothilones), we focus hereafter on reviewing 
the study findings of microtubule-targeting agent-induced neuropathy. In general, microtubule-
targeting agents (MTAs) are anticancer drugs that target and disrupt microtubule dynamics, 
resulting in mitotic arrest and cell death. Although clinically effective for cancer cells, this 
antineoplastic activity also considerably impairs the elongated microtubules found in sensory 
neurons (Figure 1.2). Early studies in mouse dorsal root ganglion cultures and rodents show 
presence of paclitaxel within peripheral nerves alone cause axonal microtubule aggregation52–54 
that effectively lead to diminished axonal transport of cargo between the cell body to nerve distal 
ends essential for synaptic function and neural maintenance55,56. These initial findings were 
further validated in rodents that were dosed with paclitaxel systemically57–59, observing 
consistent intraaxonal microtubular accumulation mainly in peripheral nerves associated with 
swollen degenerated axons, reduction in sensory nerve conduction velocities, impaired 
coordination, and altered pain perception. Studies using primary DRG, sural nerves, and other 
	 7	
neuronal cultures have suggested that paclitaxel-induced disruption of microtubule organization 
impairs axonal transport60–63. Disruption in axonal transport has also been implicated as the main 
contribution to neuropathy with other microtubule-targeting agents64,65. 
 
Figure 1.2 Proposed mechanisms for development of MTA-induced peripheral neuropathy 
include axonopathy due to distruptions in microtubule dynamics, mitochondrial function, ion 
channel activity, myelin sheaths, and degeneration of nerve endings. 
 
 
Interestingly, key studies using the Wlds mouse, a strain resistant to axonal degeneration, 
have highlighted the importance of axonal degeneration in the severity of sensory neuropathy 
after paclitaxel exposure. Wlds mice were protected against impairment of sensorimotor 
coordination, reduction in sensory nerve action potentials and sensory nerve conduction 
velocities, and diminished sensory axonal density and numbers66,67. Vincristine exposure to DRG 
cultures from Wlds mice also shown similar protective effects with axonal degeneration67,68. 
Other genetic mouse models (e.g. SARM1-deletion) resistant to axonal damage also demonstrate 
that MTA-induced peripheral neuropathy is dependent on axonal loss69. Additional studies in 
primary DRG and rodent models of CIPN have also documented that damage to the distal 
regions of the axon are necessary to initiate neuropathy, causing predominant sensory axonal 
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polyneuropathy35,36,40,70–72 and likely result in the loss of epidermal nerve fibers observed in 
human biopsies44–47 (Figure 1.2). 
 As damage in axonal transport can also affect cargo needed for mitochondrial function59 
(Figure 1.2), paclitaxel-induced neuropathic pain in rats also shows prominent amounts of 
swollen and vacuolated axonal mitochondria within sensory nerves37,73, which is not observed in 
motor nerves38. This morphological change corresponds to compromised mitochondria 
respiration, which increases oxidative stress levels in rodents in vivo74–77 and DRG in vitro 
models78. Heightened oxidative stress from paclitaxel treatment has been linked to abnormal 
excitability in afferent nerve fibers79 and may explain abnormal touch/pain sensations 
experienced by patients. Alongside oxidative stress, paclitaxel treatment has also been shown to 
release calcium from mitochondria80 in mouse pancreatic cells. Paclitaxel and vincristine 
treatments in rodent CIPN models and human neuroblastoma cell lines have corroborated these 
findings, showing abnormal cellular calcium levels can result from chemotherapy exposure81–83 
and similarly lead to mechanical hypersensitivity. A study on ixabepilone-induced neuropathy 
also observed abnormal mitochondria in both axons and Schwann cells from patient skin 
biopsies84 similarly seen with paclitaxel therapy. Interestingly, a recent study identified 
differentially expressed genes in mitochondrial dysfunction-related pathways from breast cancer 
survivors with paclitaxel-induced neuropathy85, and further implicates the role of mitochondrial 
homeostasis in microtubule-targeting agent-induced neuropathy. 
Alterations in various neuronal ion channels responsible for excitability of peripheral 
nerves have also been suggested as a contributor to MTA-induced neuropathy (Figure 1.2). 
Initial studies using primary DRG neurons revealed changes in sensory action potentials and 
gene expression of various neuronal ion channels after taxane exposure86,87, including sodium, 
	 9	
potassium, and TRP channels. Interestingly, upregulation of Nav1.7 has been shown to correlate 
with calcitonin gene-related peptide (CGRP) release87, a marker of nociception, in DRG neurons 
from rats treated with paclitaxel and patients with neuropathic pain. Another study has shown 
increased expression of calcium channels (Cav3.2) in rat DRG and spinal cord tissue after 
paclitaxel or vincristine treatments, associating with hyperexcitability88–90. Among the implicated 
ion channels, transient receptor potential (TRP) channels are the most studied due to their 
prominent role in pain and temperature sensations. Reductions in TRPV4 expression in sensory 
nerves can reduce paclitaxel-induced hyperalgesia in vivo91. Other TRP channels (i.e. TRPA1 
and TRPV1) have also been linked to paclitaxel- and vincristine-induced neuropathic pain. 
TRPA1-deficient mice release less CGRP after paclitaxel exposure92, resulting in reduced 
paclitaxel-evoked mechanical allodynia. Paclitaxel and vincristine treatments in rodents similarly 
increase TRPV1 expression in DRG neurons and paw skin93,94.  Interestingly, a recent study 
using both DRG cultures and an in vivo rodent model suggests calcium entry into TRPV1 occurs 
after paclitaxel exposure, leading to DRG cytotoxicity and neuropathic pain95. 
Lastly, neuroinflammation and other immune responses may also be involved in the 
development of MTA-induced neuropathy. Initial studies observed paclitaxel or vincristine 
treatment in rats stimulated activation of macrophages within DRG and peripheral nerves96–98, 
consequently triggering neuropathy. Later studies demonstrated that paclitaxel treatment of 
primary DRG cultures99,100 and in vivo100,101 increased monocyte chemoattractant protein-1 
(MCP-1) and signaled the infiltration of macrophages into DRG tissue, ensuing in neuronal 
apoptosis, loss of intraepidermal nerve fibers and mechanical hypersensitivity. Depletion of 
macrophages within DRG show significant prevention in development of paclitaxel-induced 
neuropathic pain100,102. Alongisde activation of MCP-1, paclitaxel and vincristine treatments 
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have also consistently shown increased expression levels of IL-1b, IL-6, TNF-a, and other 
inflammation signals in primary DRG tissues103–107, which are similarly associated with 
increased nociceptive responses such as release of pain markers (e.g., substance P and CGRP), 
reduction in intraepidermal nerve fibers, and mechanical/thermal hypersensitivities. Intriguingly, 
patients with severe neuropathy after chemotherapy treatment have been shown to have higher 
IL-6 serum concentrations when compared with patients without neuropathy symptoms108. 
Recent studies have shown that blocking these pro-inflammatory signals (i.e. IL-1, IL-6) or 
introducing anti-inflammatory cytokines (IL-10) reduce global nociceptive responses in 
paclitaxel-treated primary cultured DRG neurons and rodent models103,108, which offers a 
promising avenue for treatment of CIPN.  
 While disruption in axonal transport is the most widely-accepted mechanism for MTA-
induced neuropathy, it is still unclear which mechanisms are the primary cause for pathogenesis 
and which are secondary cellular responses after onset of peripheral degeneration. However, 
these studies have highlighted the biological complexity underlying this drug-induced toxicity, 
and underscore the need for novel approaches to enhance our understanding of how 
chemotherapeutics stimulate peripheral nerve degeneration. In particular, human reverse 
translational studies and novel in vitro models using human sensory neurons should lead to 
increased understanding of the underlying mechanisms.  
 
Genetic Association Studies Provide Clues to the Molecular Mechanisms Underlying MTA-
induced Peripheral Neuropathy 
Human genetic association studies are an important tool for identification of genetic networks 
involved in drug response or toxicity and have been increasingly applied to understand MTA-
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induced peripheral neuropathy. These genomic approaches have given us more clues as to what 
biological processes may be important in the pathophysiology underlying MTA-induced 
neuropathy, with the promise that this information can be translated into improved chemotherapy 
selection and novel strategies for the prevention and/or treatment of this dose-limiting toxicity. 
Genome-wide association studies have enabled the transition from biased candidate genes 
studies to genome-wide studies of CIPN, which have revealed additional insights into which 
genetic pathways are vital to drug-induced sensory peripheral neuropathy.  
The dose-dependent nature of MTA-induced neuropathy led to an initial focus in 
pharmacogenetic studies on candidate genes involved in drug pharmacokinetics and 
pharmacodynamics. Candidate gene studies on microtubule targeting agent-induced peripheral 
neuropathy implicated genetic polymorphisms in drug metabolizing enzymes (CYP2C8/9, 
CYP3A4/5)109–117 and transporters (ABCB1, ABCC2)113,118–123.  The first candidate gene 
studies120,124 investigated ABCB1 variants and its role in taxane-induced neuropathy, which have 
been replicated in other validation cohorts113,119,122. A decreased function ABCB1 variant is 
consistent with increased risk of neuropathy since P-glycoprotein (encoded by ABCB1) effluxes 
toxic substances out of the nervous system back into systemic circulation. Investigation of genes 
involved in vincristine pharmacokinetics revealed ABCC2 variants associated with increased 
neurotoxicity121. Other initial studies discovered susceptibility of severe neuropathy in patients 
harboring CYP2C8 and CYP3A4 polymorphisms110,113, which is consistent with taxane dose-
dependent toxicity and has been replicated in other candidate gene studies109,111,112,125. Variants 
in CYP3A5 have been shown to be more relevant than CYP3A4 to metabolism and neurotoxicity 
in patients treated with vincristine114. Additional candidate gene association studies have also 
found variants in genes related to drug targets. Polymorphisms that disrupt biological pathways 
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involving actin, tau, and microtubule regulation and function may alter taxane activity within 
sensory neurons and result in axonal degeneration. This hypothesis is emphasized by candidate 
gene studies discovering associations with variants in TUBB2A, MAPT, and GSK3B126–128 to 
sensitivity of taxane-related neuropathy. Genes involved in interactions between the actin and 
microtubule cytoskeleton (i.e., ACTG1, CAPG)129 were further highlighted in a study on 
vincristine-induced neuropathy. 
While these candidate genes studies provided fundamental insights on MTA-induced 
peripheral neuropathy, genome-wide approaches capture novel associations in an unbiased 
manner, interrogating both direct and indirect genetic effects on CIPN. Table 1.3 summarizes 
findings from genome-wide association studies on MTA-induced peripheral neuropathy to date. 
Although the early candidate gene association studies suggested neurotoxicity may be related to 
overall drug exposure, genome-wide association studies have shown that genes in nerve repair 
mechanisms seem to play a more important role than pharmacokinetic or pharmacodynamic 
genes. The first GWAS130 on paclitaxel-induced peripheral neuropathy identified three novel 
genes important in neurite growth during development (EPHA5, FZD3) and in regulation of actin 
in filopodia/lamellipodia formation (FGD4), while a recent GWAS of docetaxel-induced 
peripheral neuropathy131 identified a gene implicated in neurodegeneration (VAC14).  EPHA5, a 
gene encoding for an ephrin signaling receptor that functions to guide axon growth during 
development, was identified and replicated in additional genetic association studies of paclitaxel-
induced neuropathy132–134. Genetic association studies of vincristine-induced neurotoxicity have 
also implicated additional genes related to neuron structure, including those involved in 
microtubule/actin organization (CEP72, SYNE2)135,136 and nerve innervation (COCH)137.  Other 
taxane-induced neuropathy studies have further highlighted nerve regeneration (e.g., GPR177, 
	 13	
SBF2)138,139 as well as inflammatory (RFX2, FCAMR)138,140 responses as important biological 
mechanisms of CIPN. 
Of note, FGD4 is a known gene causal to Charcot-Marie-Tooth disease, a hereditary 
neuropathy characterized by overall peripheral nerve damage and loss of muscle. This finding 
was further highlighted by the discovery of other CMT genes (ARHGEF10 and PRX)141,142 
associated with taxane-induced neuropathy. In these cases, individuals with genetic variants in 
these genes only develop neuropathy symptoms in response to MTA exposure. It is possible that 
these individuals have compromised ability to repair nerve damage after MTA therapy, thus 
leading to a high probability of developing drug-induced neuropathy. Additionally, many of the 
implicated genes (FGD4130, EPHA4/5/6/8130, LIMK2133, ARHGEF10141,142, SBF2139, S1PR1 
(Chapter 2)) associated with taxane-induced neuropathy from GWAS and sequencing studies 
converge on Rho-GTPase signaling pathways, a critical biological process that governs axonal 
guidance and neuronal extension (i.e., formation of filopodia and lamellipodia). These findings 
suggest genetic perturbations that cause axonal degeneration or inhibit axonal regeneration 
processes may prevent the proper innervation of new epidermal layers after chemotherapy 
exposure, and potentially perpetuate the development of MTA-induced peripheral neuropathy.  
While identification of biologically relevant genes and pathways from GWAS has given 
us some intriguing findings and supports ongoing functional studies in CIPN, the biggest 
challenge for all pharmacogenetic studies is finding appropriately sized and phenotyped 
populations for replication. As a result, most of these GWAS findings remain unreplicated. 
Nonetheless, genome-wide association studies have revealed the polygenic nature of MTA-
induced peripheral neuroapthy143, and overall, suggest a role for peripheral nerve repair pathways 
in determining sensitivity to chemotherapeutic agents. The discovery and replication of more 
	 14	
genetic associations would undoubtedly lead us closer to understanding the delicate balance 
between peripheral nerve damage and repair following exposure to neurotoxic chemotherapies, 
which may offer innovative strategies for CIPN management and for early screening of CIPN 
susceptibility.  As genomic sequencing technologies advance and become more affordable, and 
standard neurotoxicity assessments become readily available, novel clinically relevant genetic 
associations will be uncovered and currently reported associations will be validated.  
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Translation of Genetic Findings using Human Sensory Neurons 
Human induced pluripotent stem cell (iPSC)-derived sensory neurons hold great promise for 
understanding the genes and pathways underlying drug-induced neuropathy, defining the 
contribution of genetic variation to the toxicity, and screening for drug targets. Recent studies 
have highlighted the use of human stem cell-derived neurons for modeling chemotherapy-
induced sensory neuronal damage131,135,153–156,144,146–152, where some have focused on translating 
the genetic findings from GWAS into molecular mechanisms that can be exploited for novel 
targets against CIPN.  Human derived sensory nociceptors originating from fibroblasts or blood 
have shown sensitivity upon exposure to various anticancer drug classes that cause 
neuropathy152,153,157, resulting in dose-dependent changes in neuronal morphology which include 
reductions of neurite length, neuron count, cell viability, and apoptosis. Other studies146–148,155 
have shown similar effects with commercially available iPSCs (iCell® neurons, Peri.4U® 
neurons) that are more robust for high-throughput screening of potential genetic targets.  
 As these iPSC-derived neurons appear to embody similar nociceptive responses to 
chemotherapy exposure as human sensory neurons, recent work has utilized these in vitro models 
for validation of GWAS findings, measuring changes to chemotherapy sensitivity after 
modulating identified genetic targets. Of note, genetically inhibiting TUBB2A in iCell® neurons 
increase paclitaxel-induced neurite retraction by ~ 20%147. Validation of AIPL1 from a genome-
wide association study (Table 1.3) on paclitaxel-induced neuropathy used the same in vitro 
model, with decreased AIPL1 expression resulting in overall protection against paclitaxel-
induced neurite morphological damage144. Similarly, Diouf et al.135 reported support for the 
involvement of CEP72 in vincristine-induced neuropathy using this in vitro model. Using iCell® 
neurons, the authors demonstrated genetically silencing CEP72, a representation of a loss of 
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function variant in the promoter of CEP72, displayed greater vincristine-induced neuronal 
damage (i.e. reduced neurite lengths and branching). While these validation studies are crucial in 
translating GWAS findings into molecular targets, it is also important to note that iCell® 
neurons are distinctly central neurons and may show differences in effect compared with 
peripheral neurons. Intriguingly, one study149 using Peri.4U® neurons, iPSC-derived 
“peripheral-like” neurons, has shown sensitivity to MTA treatments but not platinum agents or 
thalidomide. Unlike iCell® neurons that are affected by all CIPN-related drugs, this result 
suggests human iPSC-derived sensory peripheral neurons rather than iPSC-derived central 
neurons are likely the most appropriate in vitro model to recapitulate MTA-induced axonal 
degeneration. One study has used Peri4.U® neurons for validation of VAC14 in docetaxel-
induced neuropathy131 (Table 1.3), revealing siVAC14 Peri.4U neurons have less neurite 
outgrowth and less neurite branches under paclitaxel and docetaxel exposure, respectively, 
compared to a nontargeting control. Further corroborating the result found in Peri.4U® neurons, 
the authors show that Vac14-/- mice have increased nociceptive sensitivity compared to wildtype 
mice following docetaxel treatment, attesting that these in vitro models are suitable to validate 
and screen potential genetic targets associated with MTA-induced peripheral neuropathy.  
With the continuing implementation of iPSC-derived sensory neurons into 
pharmacogenetic studies, we will be able to truly isolate how patient-specific genetic variation 
determines CIPN predisposition and build a platform to screen potential tailored neuroprotective 
targets. A recent study has shown successful utilization of patient iPSC-derived sensory neurons 
to treat severe small fiber neuropathic pain151, demonstrating that such models can more 
faithfully mimic target tissues and translate patient experience.  
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Gaps in Research and Focus of this Dissertation 
The main limitation to develop therapeutic strategies against CIPN is the lack of knowledge in its 
pathophysiology across chemotherapies. With advances in genomic technologies and more 
robust functional models of CIPN, we have only begun to address the current gaps in our 
understanding of how CIPN develops. The work described herein utilizes a pharmacogenetic 
approach (Figure 1.3) using human-level data to investigate the underlying mechanisms 
contributing to MTA-induced neuropathy. Chapters 2 and 3 describe genome-wide association 
studies using genotyping and next-generation sequencing data, which were designed to discover 
novel genetic targets that are clinically relevant to MTA-induced peripheral neuropathy and 
directly provide insight on patient sensitivity to chemotherapy-induced peripheral nerve damage. 
These efforts to uncover underlying actionable markers and validate in robust model systems are 
the next critical steps to translate genomic targets into therapies for drug-induced neuropathy. As 
the importance of cancer survivors’ long-term well-being continues to gain acknowledgement, 
there is an increasing interest in effectively monitoring and controlling patient symptoms. 
Chapter 4 explored how patient genetics and early symptom monitoring may aid in the prediction 
of dose-limiting neuropathy events. The ability to predict severe MTA-induced peripheral 
neuropathy events early in treatment would considerably support clinical decisions when 
balancing chemotherapy benefit and patient quality of life. Overall, the findings from the work 
herein contribute new insights into critical genetic networks responsible for this complex drug-
induced toxicity, and will enable future studies to develop standardized tools to predict, manage, 
and treat at-risk patients genetically susceptible to MTA-induced peripheral neuropathy. 
	 21	
 
Figure 1.3 The precision medicine approach incorporates both genome-wide association studies 
and functional models to understand the molecular mechanisms underlying CIPN, with the goal 
of discovering novel strategies to prevent and treat this dose-limiting toxicity. The identification 
of genetic biomarkers will enable screening for CIPN risk, thereby improving clinical decisions. 
In vitro models to study CIPN have the potential to inform how patient susceptibility develops, 
identify novel therapeutic strategies for treatment and prevention, and test new chemical entities 
for liability for this toxicity. 
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CHAPTER 2:  Genome-Wide Meta-Analysis in CALGB 40502 and CALGB 40101 
(Alliance) Identifies a S1PR1 Genomic Region Associated with Microtubule Targeting 
Agent-Induced Sensory Peripheral Neuropathy in Breast Cancer Patients 
 
INTRODUCTION 
Microtubule-stabilizing agents such as taxanes and epothilones, are widely prescribed for 
treatment of various solid tumors. These tubulin inhibitors disrupt microtubule dynamics via 
stabilization of microtubules to primarily target and block rapidly dividing cells1, and are effective 
in treating primary and metastatic breast cancer. However, a significant amount of interindividual 
variability exists in clinical response and adverse events2. The main non-hematological dose-
limiting toxicity of microtubule-stabilizing agent therapy is sensory peripheral neuropathy. This 
nerve damage presents as distal axonal degeneration and clinically manifests as numbness or 
tingling, or painful sensations in a “glove and stocking” distribution3. Up to 50% of patients 
experience some degree of sensory peripheral neuropathy with as many as 30% reaching severe 
peripheral neuropathy (grade 3 or 4)4,5. These symptoms manifest as early as the first dosing cycle, 
and in severe cases, the symptoms persist for years after the last course of therapy6,7. Reported risk 
factors for drug-induced neuropathy include prior treatment with neurotoxic agents, frequency of 
chemotherapy dosing, high cumulative chemotherapy exposure, preexisting neuropathy and age4. 
However, these risk factors do not fully account for the observed incidence of chemotherapy-
induced peripheral neuropathy (CIPN)8.  There are currently no neuroprotective strategies that 
provide adequate clinical efficacy in preventing this toxicity and the only drug deemed at all 
effective for treatment of existing CIPN is duloxetine8. 
Human genetic association studies have been used as tools to identify critical genes 
involved in the pathophysiology of CIPN. In genetic association studies, consideration of the 
highest-ranking single nucleotide polymorphisms (SNPs) with respect to P-value suggested a 
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potential role for genes related to the regulation of neuron morphogenesis and neurodegeneration 
(EPHA4/5/6, FGD4, FZD3, ARHGEF10, VAC14) in the pathogenesis of taxane-induced 
peripheral neuropathy9–12. While most of these genetic hits did not reach genome-wide 
significance, candidate gene analyses in independent populations support the associations with two 
ephrin receptor genes10,13, FGD414, and ARHGEF1015. The primary goal in the current study was 
to conduct a meta-analysis of two cohorts of breast cancer patients (CALGB 40502 and CALGB 
40101) to extend these genomic findings and further elucidate this complex phenotype.  
CALGB 40502 was a phase III randomized three-arm study comparing nanoparticle 
albumin-bound (nab) paclitaxel or ixabepilone once per week to weekly paclitaxel as first-line 
therapy for patients with advanced breast cancer16; bevacizumab was administered in all arms of 
the study. CALGB 40101 was a randomized trial with 2x2 factorial design to test the noninferiority 
of single agent paclitaxel with doxorubicin and cyclophosphamide (AC) and the superiority of six 
cycles of treatment over four cycles17. The most common grade 3 to 4 non-hematological toxicity 
in both studies was sensory neuropathy16. Findings from the pharmacogenomic association meta-
analysis were functionally evaluated in vitro to probe the mechanistic basis of chemotherapy-
induced sensory neuron damage. 
 
MATERIALS AND METHODS 
Participants 
All study participants were enrolled in either CALGB 40101 or CALGB 40502. CALGB 40101 
was open from May 15, 2002 to July 30, 2010, enrolling 3,873 patients. CALGB 40502 was 
open from October 2008 through November 2011, enrolling a total of 799 subjects. Eligibility 
criteria for enrollment for each clinical trial study have been previously described16,17. All 
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patients provided written informed consent for both the treatment and companion 
pharmacogenetic protocols that met state, federal, and institutional guidelines in both CALGB 
40101 and 40502. Only subjects in CALGB 40101 receiving paclitaxel every two weeks were 
included in pharmacogenetic studies. 
 
Genotype Data 
Study characteristics of CALGB 40101 and CALGB 40502 are shown in Table 2.1. From the 
799 patients randomized in CALGB 40502, a total of 633 consented patients with DNA samples 
were genotyped using the Illumina HumanOmniExpressExome-8 BeadChip, interrogating 
964,055 SNPs with coverage of common variants and additional exonic content. Genotyping 
data were filtered using a standard quality control (QC) pipeline (Figure 2.1). All samples in 
CALGB 40502 were filtered for low call rate (< 0.99) or low genotyping performance; none 
were excluded. Non-autosomal SNPs were excluded, leaving 902,927 SNPs for use in additional 
sample QC. Identity-by-descent (IBD) analysis identified the presence of two closely related 
individuals, which were excluded and found later to be a plating error. An X chromosome 
heterozygosity estimation identified three genetic males that were removed, leaving 628 subjects 
for further analysis. Principal component analysis (PCA) was performed using directly 
genotyped SNPs of all 628 study subjects to determine genetic ancestry with GenABEL R 
package. A total of 485 subjects of European genetic ancestry were identified and confirmed 
with a second PCA using genotyped SNPs with the EIGENSTRAT method. Mean values for the 
first three PC vectors and eigenvectors within all patients self-declaring “White” race and “Non-
Hispanic”/ “Unknown” ethnicity were determined, resulting in 478 samples (Figure 2.2). A final 
discovery cohort of 469 samples with phenotypic and genetic information were used in the 
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primary analysis. A similar process was completed for CALGB 401019, isolating a total of 855 
individuals of European ancestry with phenotype information for further analysis. For CALGB 
40502, genetic imputation was performed with 902,927 SNPs using the Michigan Imputation 
Server18. The imputation process was completed with 1000 Genomes Phase 3 v5 as reference 
panel and phasing using ShapeIT v2.r790. A total of 863,911 genotyped SNPs was mapped to 
97.09% of the 1000G Phase 3 reference panel (Figure 2.3) and 717,432 SNPs remained after 
imputation server quality control. The imputation process yielded 45,933,061 SNPs and post-
imputation filtering included removal of any insertions and deletions, multi-allelic sites, 
monoallelic sites, and those with Rsq imputation quality score < 0.3, leaving 23,210,471 imputed 
SNPs for association analysis. 
All samples from CALGB 40101 used in the current meta-analysis were described in a 
prior GWAS9. A total of 531,729 SNPs were submitted for genetic imputation using the 
Michigan Imputation Server18. A total of 527,802 SNPs was mapped to 99.58% of the reference 
genome (Figure 2.3) with 527,802 SNPs remaining after imputation server quality control. A 
total of 47,101,766 SNPs was imputed and post-imputation filtering yielded 14,676,818 SNPs 
used for the meta-analysis. 
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Table 2.1 Study characteristics of pharmacogenetic cohorts in CALGB 40502 and CALGB 
40101 
 CALGB 40502 CALGB 40101 
Consented with DNA 633 1029 
Post Quality Control 628 1023 
White (Non-Hispanic/Non-Latino) 478 (76%) 855 (83%) 
Discovery Cohort† 469 855 
Disease Stage Locally recurrent or metastatic breast cancer 
Early-stage breast 
cancer with 0-3 
positive axillary nodes 
Drug therapy 
Paclitaxel (90 mg/m2) or  
nab-paclitaxel (150 mg/m2) or 
ixabepilone (16 mg/m2) ± 
bevacizumab weekly for 3 of 4 
weeks 
Dose-dense paclitaxel 
(175 mg/m2) biweekly 
for 4 or 6 cycles 
Reported incidence of 
peripheral neuropathy‡ 
232 (49%) 206 (24%) 
Taxane-naïve No Yes 
Chemo-naïve No Yes 
Informative competing risks to 
developing peripheral neuropathy‡ Yes No 
Genotyping array 
Illumina 
HumanOmniExpressExome-8 
BeadChip 
Illumina 
HumanHapQuad610-
Quad Genotyping 
BeadChip 
†Self-reported White (Non-Hispanic/Non-Latino) samples with complete phenotype information 
‡Within discovery cohort, where peripheral neuropathy reported as Grade 2 or higher 
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Figure 2.1 Sample and imputed genotype quality control pipeline applied to CALGB 40502. 
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Figure 2.2 The first two principal components from the genome-wide genotype data are plotted. 
Each dot represents a sample from the genotyped cohort (n = 628) and each color represents a 
self-reported race. The pink dots within the indicated circle are defined as the “White (Non-
Hispanic/Non-Latino)” discovery cohort. 
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Figure 2.3 Allele-frequency correlation from imputation of CALGB 40101 and CALGB 40502 
samples. The allele frequency of individual SNPs passing QC in CALGB 40101 (n = 527,8002) 
and CALGB 40502 (n = 717,432) were compared to the allele frequency in the 1000G Phase 3 
data.  
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Phenotype Data 
Adverse events, including chemotherapy-induced peripheral neuropathy, were graded according 
to the NCI Common Terminology Criteria for Adverse Events (NCI-CTCAE v3 in CALGB 40502; 
NCI-CTCAE v2 in CALGB 40101), defining the range of severity of neuropathy cases as Grade 
0-5. Since the incidence of the toxicity is dependent on cumulative drug exposure, sensory 
peripheral neuropathy was assessed with a dose-to-event phenotype. An MTA-induced sensory 
peripheral neuropathy event was defined as the cumulative MTA dose (mg/m2) to first instance of 
grade 2 or higher sensory peripheral neuropathy. Patients in CALGB 40101 for whom no 
neuropathy event was reported were uninformatively censored at completion of treatment (i.e., 
four or six treatment cycles). In CALGB 40502, patients were treated until unacceptable toxicity, 
other complicating disease, alternative therapy, patient withdrawal, treatment completion, 
progression or death. Patients for whom no neuropathy event was reported were informatively 
censored at time of occurrence with one of the competing risks.  
 
Statistical Analysis for Genome-wide Analysis  
Genome-wide association analyses were individually completed for each CALGB cohort. In 
CALGB 40101, the association between genotypic variation for each SNP and hazard of 
neuropathy event was tested within the framework of a Cox model using the score statistic, 
assuming uninformative censoring. In CALGB 40502, each SNP was tested for an association 
with cause-specific hazard of neuropathy event within the framework of a Cox model using the 
Wald statistic, stratifying for treatment arm and adjusting for age. In each case, genotypic 
variation was inferred using imputed allele dosage for untyped SNPs and associations were 
tested assuming an additive genotype-phenotype effect. This analysis was conducted under the R 
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statistical environment19 3.3 with the GenABEL20, survival21, cmprsk22, qqman23, and ggplot224 
packages. Per SNP summary statistics were further used to conduct an inverse-variance weighted 
meta-analysis using the METAL software25. The reported P-values and confidence interval 
estimates have not been adjusted to account for multiple testing or imputation error. This 
discovery analysis used ranking of unadjusted P-values for feature selection and prioritization for 
additional analyses.  
 
In silico Functional Analysis 
Selected variants associated with MTA-induced peripheral neuropathy underwent bioinformatic 
analysis to identify those most likely to disrupt gene function. Each variant of interest was 
assessed with HaploReg v4.1 (https://pubs.broadinstitute.org/mammals/haploreg/haploreg.php), 
GTEx v8 (https://gtexportal.org/home/), UCSC Genome Browser (https://genome.ucsc.edu/), 
SEdb v1.03 (http://www.licpathway.net/sedb/), and HACER 
(http://bioinfo.vanderbilt.edu/AE/HACER/); additional variants were further prioritized if 
annotated genes were linked to previous studies of chemotherapy-induced peripheral neuropathy. 
UCSC Genome Browser was used to visually interrogate genomic regions of interest for 
enrichment of regulatory elements using Open Regulatory Annotation database26, GeneHancer 
database27, brain methylation28 and histone marks29, and ENCODE Project30 data, which 
included ChIP-seq histone modification peaks, transcription levels from RNA-seq, transcription 
factor ChIP-seq clusters, DNase I hypersensitivity clusters, and predicted genome segmentations 
(Segway, ChromHMM, and combined algorithms). HaploReg31 was used to explore noncoding 
SNPs and their proxy SNPs (LD r2 > 0.6) for further regulatory function using ChIP-seq, DNAse 
I hypersensitivity, and ChromHMM chromatin state predictions from the Roadmap 
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Epigenomics32 and ENCODE Project30. Expression and splicing qualitative trait loci associated 
with these SNPs were summarized from the GTEx Portal33. Human super-enhancer regions were 
also identified from SEdb34, a comprehensive human super-enhancer database using a collection 
of H3K27ac ChIP-seq data from NCBI Gene Expression Omnibus, ENCODE Project, Roadmap 
Epigenomics Project, and Genomics of Gene Regulation Project. These super-enhancer regions 
were queried for predicted enhancer-gene interactions using the HACER database35 that 
incorporates FANTOM5, GTEx eQTL data, and experimentally validated interactions from 
4DGenome, Hi-C, ChIA-PET, HiChIP and Capture Hi-C data. 
 
iPSC-Induced Sensory Neuron Differentiation and Culture 
Human induced pluripotent stem cell (iPSC) line WTC was previously validated and 
established36. WTC was differentiated into peripheral sensory neurons using a previously 
described protocol37. Briefly, human iPSCs were cultured in mTesR medium (STEMCELL 
Technologies, cat. no. 05850; Cambridge, MA) on matrigel (Corning, cat. no. 356234; Corning, 
NY) coated plates at a density of 50,000 cells/cm2. Neural differentiation was initiated (days 0-5) 
using KSR medium and SMAD inhibitors: 100 nM LDN-193189 (Selleck, cat. no. S7507; 
Houston, TX) and 10 µM SB431542 (Selleck, cat. no. S1067; Houston, TX). The KSR medium 
consisted of 80% knockout DMEM, 20% knockout serum replacement, 2 mM GlutaMAX 
(100X), MEM nonessential amino acids (100X) and 0.1 nM β-mercaptoethanol (ThermoFisher, 
cat. nos. 10829018, 10828028, 35050061, 11140050, 21985023; Waltham, MA). Early 
nociceptor differentiation began on day 2 with introduction of 3 µM CHIR99021, 10 µM 
SU5402, and 10 µM DAPT (Selleck, cat. nos. S1263, SU5402, S2215; Houston, TX). N2 
medium (ThermoFisher, cat. no. 17502048; Waltham, MA) was added in stepwise increments of 
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25% starting at day 4 until reaching 100% on day 10. N2 medium was composed of 50% 
DMEM/F12 medium with 100X N2 supplement (ThermoFisher, cat. nos. 11320033, 17502048; 
Waltham, MA) and 50% Neurobasal medium with 50X B27 supplement (ThermoFisher, cat. 
nos. 21103049, 17504044; Waltham, MA). Mature nociceptors were induced on day 12 and 
maintained with neuronal growth factors (10 ng/ml human b-NGF, BDNF, GDNF, and NT3; 
PeproTech, cat. nos. 450-01, 450-02, 450-10, 450-03; Rocky Hill, NJ). On day 12, human iPSCs 
were seeded at ~35,000 cells/cm2 and cultured on 96-well plates (Greiner Bio-One, cat. no. 
655090; Monroe, NC) triple coated with 15 µg/ml poly-L-ornithine hydrobromide (Sigma-
Aldrich, cat. no. P3655; St. Louis, MO), 2 µg/ml laminin-1 (Cultrex R&D Systems, cat. no. 
3400-010-1; Minneapolis, MN), and 2 µg/ml fibronectin (BD Biosciences, cat. no. 356008; San 
Jose, CA). Cells were differentiated and maintained at 37ºC and 5% CO2. A single differentiation 
originating from iPSCs was considered one independent experiment. 
 
In vitro Neurotoxicity Studies 
After iPSCs were differentiated into mature nociceptors (day 35+), iPSC-SNs were treated with 
paclitaxel (Sigma-Aldrich, cat. no. T7402; St. Louis, MO) with or without FTY720 (Cayman 
Chemical; cat. no. 11975) or W146 (Cayman Chemical, cat. no. 10009109; Ann Arbor, MI), and 
compared to those treated with 0.2% DMSO (Sigma-Aldrich, cat. no. D2650; St. Louis, MO) as 
a vehicle control. After 48 hours of drug treatment, sensory neurons were fixed in 4% 
paraformaldehyde for 15 min at room temperature. After washing with PBS, cells were 
permeabilized with 0.25% Triton-X (Sigma-Aldrich; Saint Louis, MO) in PBS for 10 min at 
room temperature.  Cells were then blocked with the addition of 10% goat serum (Jackson 
ImmunoResearch Laboratories, Inc.; West Grove, PA) in 1% BSA and 0.5% Tween-20 blocking 
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solution for 1 hour. Fixed cells were incubated overnight at 4ºC with anti-TUJ1 antibody 
(Covance, cat. no. MRB-435P; Princeton, NJ). Goat anti-rabbit secondary antibody (Life 
Technologies, cat. no. A-11008; Carlsbad, CA) was added in blocking buffer for 1 hour. After 
PBS washes, DAPI stain (ThermoFisher, cat. no. D1306; Waltham, MA) was added to stain for 
nuclei. Imaging was performed at 20X magnification using the IN Cell Analyzer 2000 (GE 
Healthcare Life Sciences; Pittsburgh, PA).  
 
Imaging Data Analysis 
Workflow of the imaging analysis is shown in Figure 2.4. Nine raw images were generated from 
each well, representing a field-of-view of 15.95 mm2 (2048 x 2048 pixels; 47% of well area). 
These images were batch processed through an imaging processing software, MIPARTM, with a 
custom-built algorithm to analyze measurements for chemotherapy-induced neuronal damage. 
This algorithm generates optimized grayscale images by reducing overall noise and minimizing 
the amount of non-specific staining to identify and quantify the neurite networks within each 
field-of-view image. A subsequent segmentation algorithm was performed to estimate nuclei 
within each field-of-view image. After processing, each image or field-of-view yielded 
measurements of total neurite area and neuron count. Neurite area was defined by the total area 
of pixels captured within the identified TUJ1-stained network for each image. Cell counts were 
designated with DAPI-stained nuclei, rejecting DAPI-stained particles less than 50 pixels to 
exclude non-specific DAPI staining. To get a global measurement for each well, total neurite 
area and total cell count were generated by summing measurements across the nine field-of-view 
images. Processed images included further in the analysis were required to pass quality control 
on a per-well basis to assess the quality of the neurons and images (Figure 2.4). Per-well images 
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were stitched together using an in-house script to batch process all nine field-of-view images, 
using the Grid/Collection Stitching plugin in Fiji. Wells were only included if neurites cover ≥ 
50% of the entire well, no more than 3 field-of-view images (out of 9) contained out-of-focus 
images, and a majority of the signal intensities captured were not from artifacts.  
 
Figure 2.4 Quality control workflow of imaging analysis with field-of-view images. 
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Statistical Analysis for Image Analysis 
For each experiment, all drug treatments were completed with 6-8 replicates on the same plate 
and raw neurite area measurements and cell counts from imaging data were averaged to obtain a 
mean total neurite area/cell count per condition. Mean total neurite areas and mean total cell 
counts were expressed as a ratio of drug-treated to vehicle-treated samples. Differences between 
relative ratios for the treatment groups were tested for significance by one-way ANOVA test 
using the function aov and subsequent post-hoc multiple comparisons using unpaired, two-sided 
Student’s t-test with the function t.test in R19 version 3.5.3. The effect of S1PR1 modulators on 
paclitaxel effects were assessed by comparison to paclitaxel-treated cells. Experiments were 
repeated three times with independent neuron differentiations and the results represent the mean 
phenotype measurements from each differentiation.  The reported P-values and confidence 
interval estimates have not been adjusted for multiple testing.  
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RESULTS 
Of the 799 individuals randomized to the three-arm treatment in CALGB 40502, only 615 
subjects were genotyped and had complete phenotype information. Patient characteristics of the 
CALGB 40502 subjects are listed in Table 2.2; the distribution of age, race, ethnicity, prior 
taxane status, and tumor subtype in the pharmacogenetics cohort was similar to the entire clinical 
trial cohort. Patient characteristics for the CALGB 40101 subjects were previously summarized9, 
and differences in sample size, disease stage, drug therapy, and genotyping arrays between the 
two cohorts are described in Table 2.1. The main non-hematological toxicity in CALGB 40502 
and CALGB 40101 was sensory peripheral neuropathy with reported event rates of grade 2 or 
higher of 49% and 24%, respectively (Table 2.1). A similar cumulative incidence of peripheral 
neuropathy was observed regardless of treatment arm in CALGB 40502 (Figures 2.5 and 2.6), 
where risk of developing peripheral neuropathy was a function of cumulative chemotherapy 
dose. The main competing risk for developing peripheral neuropathy in the nab-paclitaxel arm 
was disease progression or death while other competing risks, such as other adverse events, other 
complicating disease, alternative therapy, patient refusal, and treatment completion were more 
likely to lead to censoring for the peripheral neuropathy phenotype in the paclitaxel and 
ixabepilone arms.  
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Table 2.2 Patient demographics in CALGB 40502 
  Pharmacogenetic Cohort† 
(N = 615) 
No. (%) 
Clinical Trial 
(N = 799) 
No. (%) 
Age (yrs) 20-49 164 (27) 218 (27) 
50-69 390 (63) 500 (63) 
70+ 61 (10) 81 (10) 
Race‡ White 501 (81) 640 (80) 
Black 81 (13) 113 (14) 
Other 23 (4) 32 (4) 
Unknown 10 (2) 14 (2) 
Ethnicity‡ Hispanic or Latino 31 (5) 47 (6) 
Non-Hispanic 548 (89) 712 (89) 
Unknown 36 (6) 40 (5) 
Taxane as 
adjuvant therapy 
Yes 270 (44) 352 (44) 
No 345 (56) 447 (56) 
Tumor subtype ER or PgR unknown/missing 0 (0) 16 (2) 
ER or PgR positive 443 (72) 573 (72) 
ER and PgR negative 172 (28) 210 (26) 
ER: estrogen receptor; PgR: progesterone receptor 
†Genotyped samples with complete phenotype information 
‡Self-reported race and ethnicity 
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Figure 2.5 Cumulative incidence plot of chemotherapy-induced peripheral neuropathy (A: 
paclitaxel; B: nab-paclitaxel; C: ixabepilone) and informative competing events as a function of 
cumulative dose (mg/m2) to event for all subjects in the pharmacogenetics discovery cohort of 
CALGB 40502. Top left inset displays the entire range of cumulative doses, where the boxed 
area denotes where ~75% of the data lies (Figure 2.6) and is represented in the larger plot. 
 
 
Figure 2.6 Distribution of cumulative dose-to-first instance of grade 2 or higher peripheral 
neuropathy for each treatment arm in CALGB 40502, where 75% of the distribution lies left of 
the blue vertical line and represents the cumulative doses used to generate cumulative incidence 
plots in Figure 2.5. 
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The meta-analysis of the SNP associations from CALGB 40101 and CALGB 40502 were 
filtered for SNPs with a minor allele frequency of ≥5% in at least one of the two cohorts. None 
of the resulting SNPs reached genome-wide significance, although 18 linkage disequilibrium-
pruned SNPs (r2 ≥ 0.7) had P < 10-5 (Table 2.3; Figures 2.7 and 2.8). The 18 SNPs with the 
lowest P values were filtered for further support of association from SNPs in high linkage 
disequilibrium with the identified SNP and expression in human dorsal root ganglion (DRG)38. 
SNPs in genomic regions annotated to C9orf106, SLITRK1, KLHL1, ZBBX, LOC100129716, and 
SEPT5 had limited linkage support from visual inspection of LocusZoom39 plots (Figures 2.9-
2.11) and 11 SNPs were annotated to genes that are not detected in human DRG38 (ZFPM2 
(three independent SNPs), C9orf106, KLHL1, SUGCT (two independent SNPs), ZBBX, 
LOC100129716, ADGRB3 and CNGB1). Based on the expression and linkage support filtering 
(Figures 2.12-2.17), additional analyses were only considered for the genomic regions around 
seven SNPs (rs74497159, rs17076837, rs10771973, rs11076190, rs9623812, rs2060717, 
rs2188156); while there was no support from SNPs in high linkage disequilibrium for a true 
association within the genomic region surrounding rs17076837 and rs2188156, these SNPs were 
annotated to the SLITRK1 and SEPT5 genes that are highly expressed in the human DRG. Six of 
the remaining seven SNPs were associated with increased risk of MTA-induced peripheral 
neuropathy while a single SNP was protective. Cumulative incidence plots for MTA-induced 
peripheral neuropathy stratified by each of the seven SNPs of interest are shown in Figures 2.18-
2.24. Interestingly, the association of rs11076190 and rs2188156 with peripheral neuropathy is 
driven by the paclitaxel-treated patients.  
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Table 2.3 Top ranking SNPs for meta-analysis using cumulative dose to first instance of Grade 2 
or higher peripheral neuropathy event. 
    CALGB 40101 CALGB 40502 META 
SNP* Chr Alleles† Gene MAF Effect P MAF Effect P P Direction 
rs74497159 1 T>G 168 kb 3’ of S1PR1 0.065 0.591 5.96E-04 0.055 0.693 1.59E-04 3.62E-07 ++ 
rs3110366 8 T>A 142 kb 5’ of ZFPM2 0.204 -0.394 1.20E-03 0.198 -0.446 2.51E-04 1.07E-06 -- 
rs77526807 9 G>T 39 kb 3’ of C9orf106 0.053 0.818 4.32E-04 0.059 0.764 1.14E-03 1.66E-06 ++ 
rs17076837 13 C>G 382 kb 3’ of SLITRK1 0.135 0.578 7.72E-06 0.124 0.304 2.78E-02 1.85E-06 ++ 
rs61963755 13 T>A intronic region of KLHL1 0.050 0.674 3.60E-04 0.055 0.630 1.56E-03 1.88E-06 ++ 
rs2342780 8 T>A 68 kb 5’ of ZFPM2 0.069 -0.788 8.07E-06 0.064 -0.432 3.81E-02 2.06E-06 -- 
rs10771973 12 G>A intronic region of FGD4 0.311 0.451 3.91E-06 0.301 0.203 3.65E-02 2.15E-06 ++ 
rs2342791 8 T>C 43 kb 5’ of ZFPM2 0.164 -0.414 1.03E-03 0.162 -0.430 7.43E-04 2.53E-06 -- 
rs11076190 16 T>C 8 kb 3’ of CX3CL1 0.060 0.738 3.18E-05 0.063 0.453 1.38E-02 2.55E-06 ++ 
rs78777495 7 A>T 67 kb 3’ of SUGCT 0.107 0.602 1.11E-05 0.097 0.328 4E-02 2.99E-06 ++ 
rs9623812 22 A>T intronic region of SCUBE1 0.330 -0.340 3.70E-03 0.335 -0.387 2.60E-04 3.23E-06 -- 
rs2060717 7 G>A intronic region of CALU 0.069 0.496 4.35E-03 0.066 0.735 1.61E-04 3.48E-06 ++ 
rs6788186 3 T>C 696 kb of 3’ ZBBX 0.267 0.282 2.11E-02 0.257 0.476 4.11E-05 5.08E-06 ++ 
rs78017515 7 A>G 87 kb 3’ of SUGCT 0.069 0.621 1.43E-04 0.059 0.488 1.14E-02 5.72E-06 ++ 
rs13168251 5 T>G 718 kb 3’ of LOC100129716 0.111 0.295 4.18E-02 0.105 0.664 1.13E-05 6.54E-06 ++ 
rs777619 6 T>C 487 kb 5’ of ADGRB3 0.193 0.416 1.54E-04 0.189 0.315 1.48E-02 8.13E-06 ++ 
rs2188156 22 G>A 65 kb 5’ of SEPT5 0.051 0.800 1.90E-05 0.052 0.394 5.28E-02 8.23E-06 ++ 
rs57940640 16 G>A intronic region of CNGB1 0.064 0.552 1.65E-03 0.068 0.607 1.64E-03 8.74E-06 ++ 
SNP: single nucleotide polymorphism, Chr: chromosome, MAF: minor allele frequency 
*SNPs listed are filtered for P < 10-5 and LD-pruned (r2 ≥	0.7) to the top-ranking SNP within each genomic region.  
†Alleles are denoted Major>Minor allele 
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Figure 2.7 Manhattan plot of meta-association analysis in CALGB 40502 and CALGB 40101. 
Genome-wide association test results are shown as –log10 transformed P-values for the Cox 
proportional hazards analysis indicated on the y-axis. SNPs are plotted by chromosomal location 
and is displayed on the x-axis. The dark blue horizontal line denotes P = 10-5 and the red 
horizontal line denotes genome-wide significance (P = 10-8). 
 
 
Figure 2.8 Quantile-quantile plot of meta-analysis from genome-wide association tests in 
CALGB 40502 and CALGB 40101. Observed and predicted P-value relationships are plotted for 
the Cox proportional hazard model. The solid line and shaded area show the expected 
distribution with 95% CIs assuming no inflation of statistics.  
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Figure 2.9 LocusZoom plots for genomic regions around rs77526807 located 39 kb 3’ of 
C9orf106 (top panel) and rs17076837 located 382 kb 3’ of SLITRK1 (bottom panel). 
Associations with cumulative dose to first instance of grade 2+ peripheral neuropathy for 
analyzed SNPs are shown on a –log10(P-value) scale. Dot color indicates the strength of linkage 
disequilibrium (r2) between the indicated SNP and each SNP in these genomic regions. Plots 
were produced using LocusZoom (http://locuszoom.sph.umich.edu/).  
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Figure 2.10. LocusZoom plots for associations microtubule targeting agent-induced peripheral 
neuropathy in the genomic regions around rs61963755 located within an intronic region of 
KLHL1 (top panel) and genomic region around rs6788186 located in a gene desert (bottom 
panel). Associations with cumulative dose to first instance of grade 2+ peripheral neuropathy for 
analyzed SNPs are shown on a –log10(P-value) scale. Dot color indicates the strength of linkage 
disequilibrium (r2) between the indicated SNP and each SNP in this genomic region. Plots were 
produced using LocusZoom (http://locuszoom.sph.umich.edu/). 
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Figure 2.11 LocusZoom plots for associations with microtubule targeting agent-induced 
peripheral neuropathy in the genomic regions around rs13168251 located in a gene desert (top 
panel) and rs2188156 located 63 kb 5’ of SEPT5 (bottom panel). Associations with cumulative 
dose to first instance of grade 2+ peripheral neuropathy for analyzed SNPs are shown on a –
log10(P-value) scale. Dot color indicates the strength of linkage disequilibrium (r2) between the 
indicated SNP and each SNP in these genomic regions. Plots were produced using LocusZoom 
(http://locuszoom.sph.umich.edu/). 
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Figure 2.12 LocusZoom plot of the associations with microtubule targeting agent-induced 
peripheral neuropathy in the genomic region around rs74497159 located downstream of S1PR1, 
a gene which encodes for sphingosine-1-phosphate receptor 1. Associations with cumulative 
dose to first instance of grade 2+ peripheral neuropathy for analyzed SNPs are shown on a –
log10(P-value) scale. Dot color indicates the strength of linkage disequilibrium (r2) between the 
indicated SNP and each SNP in this genomic region. Plot was produced using LocusZoom 
(http://locuszoom.sph.umich.edu/). 
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Figure 2.13 LocusZoom plots of the associations with microtubule targeting agent-induced 
peripheral neuropathy in the genomic region around top-ranking independent SNPs (rs3110266, 
rs2342780, and rs2342791) annotated to the 5’ region of ZFPM2. Associations with cumulative 
dose to first instance of grade 2+ peripheral neuropathy for analyzed SNPs are shown on a –
log10(P-value) scale. Dot color indicates the strength of linkage disequilibrium (r2) between the 
indicated SNP and each SNP in this genomic region. Plot was produced using LocusZoom 
(http://locuszoom.sph.umich.edu/).  
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Figure 2.14 LocusZoom plots for the associations with microtubule targeting agent-induced 
peripheral neuropathy in the genomic region around rs10771973 located within an intronic 
region of FGD4 (top panel) and genomic region around rs11076190 located 8 kb from 3’ of 
CX3CL1 (bottom panel). Associations with cumulative dose to first instance of grade 2+ 
peripheral neuropathy for analyzed SNPs are shown on a –log10(P-value) scale. Dot color 
indicates the strength of linkage disequilibrium (r2) between the indicated SNP and each SNP in 
this genomic region. Plot was produced using LocusZoom (http://locuszoom.sph.umich.edu/).  
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Figure 2.15 LocusZoom plots for the associations with microtubule targeting agent-induced 
peripheral neuropathy in the genomic region around rs78777495 and rs78017515 located 67 kb 
and 87 kb from 3’ end of SUGCT, respectively. Associations with cumulative dose to first 
instance of grade 2+ peripheral neuropathy for analyzed SNPs are shown on a –log10(P-value) 
scale. Dot color indicates the strength of linkage disequilibrium (r2) between the indicated SNP 
and each SNP in this genomic region. Plot was produced using LocusZoom 
(http://locuszoom.sph.umich.edu/).  
	 75	
 
 
Figure 2.16 LocusZoom plots for the associations with microtubule targeting agent-induced 
peripheral neuropathy in the genomic region around rs9623812 located within an intronic region 
of SCUBE1 (top panel) and around rs2060717 located within an intronic region of CALU 
(bottom panel). Associations with cumulative dose to first instance of grade 2+ peripheral 
neuropathy for analyzed SNPs are shown on a –log10(P-value) scale. Dot color indicates the 
strength of linkage disequilibrium (r2) between the indicated SNP and each SNP in these 
genomic regions. Plots were produced using LocusZoom (http://locuszoom.sph.umich.edu/).  
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Figure 2.17 LocusZoom plots for the associations with microtubule targeting agent-induced 
peripheral neuropathy in the genomic region around rs777619 located in a gene desert (top 
panel) and genomic region around rs57940640 located within an intronic region of CNGB1 
(bottom panel). Associations with cumulative dose to first instance of grade 2+ peripheral 
neuropathy for analyzed SNPs are shown on a –log10(P-value) scale. Dot color indicates the 
strength of linkage disequilibrium (r2) between the indicated SNP and each SNP in this genomic 
region. Plot was produced using LocusZoom (http://locuszoom.sph.umich.edu/). 
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Figure 2.18 Cumulative incidence plot for chemotherapy-induced peripheral neuropathy 
stratified by rs74497159 genotype in CALGB 40101(A) and CALGB 40502 (B, paclitaxel; C, 
nab-paclitaxel; D, ixabepilone). Top left insert displays the entire range of cumulative doses, 
where the boxed area denotes where ~75% of the data lies (Figure 2.5) and is represented in the 
larger plot. The number of individuals with each genotype is noted in parentheses. The allele risk 
for peripheral neuropathy events without other competing events are shown in the plots for 
CALGB 40502 (B-D). 
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Figure 2.19 Cumulative incidence plot for chemotherapy-induced peripheral neuropathy 
stratified by rs17076837 (C>G) genotype in CALGB 40101(A) and CALGB 40502 (B, 
paclitaxel; C, nab-paclitaxel; D, ixabepilone). Top left insert displays the entire range of 
cumulative doses, where the boxed area denotes where ~75% of the data lies and is represented 
in the larger plot. The number of individuals with each genotype is noted in parentheses. The 
allele risk for peripheral neuropathy events without other competing events are shown in the 
plots for CALGB 40502 (B-D).  
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Figure 2.20 Cumulative incidence plot for chemotherapy-induced peripheral neuropathy 
stratified by rs10771973 (G>A) genotype in CALGB 40101(A) and CALGB 40502 (B, 
paclitaxel; C, nab-paclitaxel; D, ixabepilone). Top left inset displays the entire range of 
cumulative doses, where the boxed area denotes where ~75% of the data lies and is represented 
in the larger plot. The number of individuals with each genotype is noted in parentheses. The 
allele risk for peripheral neuropathy events without other competing events are shown in the 
plots for CALGB 40502 (B-D). 
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Figure 2.21 Cumulative incidence plot for chemotherapy-induced peripheral neuropathy 
stratified by rs11076190 (T>C) genotype in CALGB 40101(A) and CALGB 40502 (B, 
paclitaxel; C, nab-paclitaxel; D, ixabepilone). Top left insert displays the entire range of 
cumulative doses, where the boxed area denotes where ~75% of the data lies and is represented 
in the larger plot. The number of individuals with each genotype is noted in parentheses. The 
allele risk for peripheral neuropathy events without other competing events are shown in the 
plots for CALGB 40502 (B-D).  
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Figure 2.22 Cumulative incidence plot for chemotherapy-induced peripheral neuropathy 
stratified by rs9623812 (A>T) genotype in CALGB 40101(A) and CALGB 40502 (B, paclitaxel; 
C, nab-paclitaxel; D, ixabepilone). Top left insert displays the entire range of cumulative doses, 
where the boxed area denotes where ~75% of the data lies and is represented in the larger plot. 
The number of individuals with each genotype is noted in parentheses. The allele risk for 
peripheral neuropathy events without other competing events are shown in the plots for CALGB 
40502 (B-D).  
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Figure 2.23 Cumulative incidence plot for chemotherapy-induced peripheral neuropathy 
stratified by rs2060717 (G>A) genotype in CALGB 40101(A) and CALGB 40502 (B, paclitaxel; 
C, nab-paclitaxel; D, ixabepilone). Top left insert displays the entire range of cumulative doses, 
where the boxed area denotes where ~75% of the data lies and is represented in the larger plot. 
The number of individuals with each genotype is noted in parentheses. The allele risk for 
peripheral neuropathy events without other competing events are shown in the plots for CALGB 
40502 (B-D). 
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Figure 2.24 Cumulative incidence plot for chemotherapy-induced peripheral neuropathy 
stratified by rs2188156 (G>A) genotype in CALGB 40101(A) and CALGB 40502 (B, paclitaxel; 
C, nab-paclitaxel; D, ixabepilone). Top left insert displays the entire range of cumulative doses, 
where the boxed area denotes where ~75% of the data lies and is represented in the larger plot. 
The number of individuals with each genotype is noted in parentheses. The allele risk for 
peripheral neuropathy events without other competing events are shown in the plots for CALGB 
40502 (B-D). 
 
Bioinformatic analysis of the genomic regions surrounding the seven SNPs chosen for 
further analysis was carried out to understand the potential functional effects of genetic variation 
on gene expression and function; the results from these in silico analyses are summarized in 
Table 2.4. Examination of ENCODE data tracks (UCSC Genome Browser; 
https://genome.ucsc.edu) identified histone acetylation and methylation marks, DNase peaks, 
multiple transcription factor binding sites, and predicted functional activity from genome 
segmentation algorithms within the genomic regions surrounding rs74497159, rs10771973, 
rs11076190, rs9623812 and rs2060717 (Figures 2.25-2.31). Further evidence that these SNPs are 
	 84	
located in transcriptionally active regions include classification as super-enhancers that interact 
with multiple genes. In some cases, the predicted enhancer region is expected to directly interact 
with the annotated gene to control its expression (Table 2.4). For example, a SNP annotated to 
S1PR1 (rs74497159) is located downstream of the 3’ end of this gene in a super-enhancer region 
that interacts with SIPR1. Similarly, the intronic SNP of FGD4 (rs10771973) lies adjacent to the 
last exon within a predicted transcriptional transition or elongation region and interacts directly 
with FGD4.  
 
Figure 2.25 rs74497159 (location denoted by dark red line) lies within a predicted enhancer 
region 168 kb 3’ of S1PR1 surrounded with multiple active regulatory elements from ENCODE 
data, including H3K27Ac peaks, multiple transcription factor binding sites, and flanking DNase 
hypersensitivity/open chromatin peaks. 
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Figure 2.26 rs17076837 (location denoted by dark red line) lies 382 kb 3’ of SLITRK1 within a 
low activity genomic region based on histone marks, DNase I hypersensitivity and predicted 
genome segmentations (ChromHMM, Segway, combined algorithms) using ENCODE data.
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Figure 2.27 Bioinformatic analysis of the genomic region around rs10771973 (location denoted 
by dark red line) that lies within an intronic region of FGD4 adjacent to the last exon. This SNP 
is in a predicted transcriptional elongation region based on ENCODE data.  
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Figure 2.28 rs11076190 (location denoted by dark red line) lies 8 kb 3’ of CX3CL1 within an 
active transcription factor binding site based on ENCODE data, Open Regulatory Annotation 
and H3K4me3 peak in young NeuN+ brain samples.  
 
 
Figure 2.29 rs9623812 (location denoted by dark red line) lies within an intronic region of 
SCUBE1 and is predicted to be an active regulatory region based on H3K4 methylation marks, 
DNAse I hypersensitivity clusters and genome segmentations (ChromHMM, Segway, combined 
algorithms) using ENCODE data. This regulatory region is predicted to hold enhancer activity in 
embryonic stem cells (H1-hESC).  
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Figure 2.30 rs2060717 (location denoted by dark red line) lies within an intronic region of 
CALU with substantial promoter activity based on H3K27Ac marks, H3K4Me1 marks, 
H3K4Me3 marks, transcription binding factor sites, DNase I hypersensitivity clusters and 
genome segmentation predictions (ChromHMM, Segway, combined algorithms) using ENCODE 
and GeneHancer data. 
  
	 89	
 
Figure 2.31. rs2188156 (location denoted by dark red line) lies 63 kb 3’ of SEPT5 within a low 
activity genomic region based on histone marks, DNase I hypersensitivity and predicted genome 
segmentations (ChromHMM, Segway, combined algorithms) using ENCODE data. 
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Interestingly, intronic SNP rs10771973 is significantly associated with splicing 
quantitative trait loci in tibial nerve tissue (P = 1.2E-11, GTEx33), suggesting that this variant 
may regulate alternative splicing of pre-mRNA levels and affect the overall FGD4 gene 
expression. rs11076190 is located in a genomic cluster with several chemokines (Figure 2.28) 
and is annotated within a FOXA1 transcription factor binding site linked to CX3CL1 (Open 
Regulatory Annotation, ORegAnno, track; Figure 2.28). SNPs within linkage disequilibirum 
with rs10771973 (FGD4), rs11076190 (CX3CL1) and rs2060717 (CALU) are each associated 
with expression quantitative trait loci and splicing quantitative trait loci, indicating potential 
relevance for regulation of gene expression. In contrast, there is little evidence that rs17076837 
annotated downstream of the 3’ end of SLITRK1 (Figure 2.26) or a SNP (rs2188156) annotated 
upstream of the 5’ end of SEPT5 (Figure 2.31) lie within regulatory regions. 
While the bioinformatic analysis highlights the potential functional activity for five SNPs 
of interest, the annotated genes from three of the five SNPs (rs74497159/SIPR1, 
rs10771973/FGD4, and rs11076190/CX3CL1) are linked to CIPN (Table 2.4). For functional 
validation, we focused on the gene annotated to the genomic region with the highest ranking 
based on P-value for association to MTA-induced peripheral neuropathy from our genome-wide 
meta-analysis, S1PR1. Since rs74497159 is annotated to the S1PR1 gene and this SNP and others 
in linkage disequilibrium are in a super-enhancer region that controls the expression of S1PR1, 
the effect of modulation of S1PR1 functional activity was tested in human iPSC-SNs.  
The human iPSC-SNs were generated following a published protocol and yield neurons 
expressing expected nociceptor markers37. Based on paclitaxel dose-response studies, paclitaxel 
treatment (1 µM) for 48 hours in the iPSC-SNs had no significant effect on caspase-3/7 activity 
and decreased cellular ATP levels by <30%, indicating limited cytotoxicity under the conditions 
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used (data not shown).  Drug-induced neurotoxicity is phenotypically characterized by a 
distinctive loss of neurites and a reduction in neurite network complexity without a decrease in 
total cell count (Figure 2.32-2.34), which was quantified by total neurite area stained for bIII-
tubulin and number of DAPI-stained nuclei. There was no significant effect of any treatment on 
cell numbers, consistent with limited cytotoxicity from paclitaxel and other chemicals. Treatment 
with 1 µM paclitaxel alone resulted in more than 50% decrease in neurite staining (49-64% 
reduction, P < 0.01; Figure 2.32) compared to vehicle-treated sensory neurons, demonstrating 
paclitaxel-induced damage to the overall neurite networks. Treatment with 1 µM S1PR 
functional antagonist FTY720 (0.3-29% reduction) and 1 µM S1PR1 antagonist W146 (0.6-14% 
reduction) had little to no effect on neurite area (Figures 2.32 and 2.33).  Combined treatment of 
the iPSC-SNs with paclitaxel and FTY720 resulted in partial protection against paclitaxel-
induced neuronal damage (33-55% increase in neurite area relative to paclitaxel treatment, P < 
0.05) (Figures 2.32 and 2.33). The combination of paclitaxel and W146 had minimal effect on 
the paclitaxel-induced loss of neurite area (4-21% increase in neurite area relative to paclitaxel 
treatment; Figures 2.32 and 2.33).  
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Figure 2.32 Inhibition of S1PR signaling attenuates paclitaxel-induced neuronal damage. (A) 
Representative per-well images of differentiated sensory neurons (D35+) derived from induced 
pluripotent stem cells used to investigate S1PR signaling in paclitaxel-induced neuronal damage. 
Differentiated neurons were treated with 1 µM paclitaxel for 48 hours in the absence and 
presence of a S1PR1 inhibitor (W146; 1 µM) or a S1PR1 functional antagonist (FTY720; 1 µM). 
The cells are stained for bIII tubulin and staining was quantified as total neurite area. All images 
shown are from a single experiment. Scale bar indicates 1 mm. (B) Quantification of mean total 
neurite area from bIII tubulin staining after drug treatments in three independent differentiations. 
Each data point represents the mean measurement of 6-8 replicates from a single independent 
differentiation and is expressed relative to vehicle controls. The coefficient of variation in 
vehicle-treated neurites ranges from 11-24%. Raw values used to calculate the means are shown 
in Figure 2.33. Relative mean neurite areas were tested for differences across treatments by one-
way ANOVA (P = 6E-05) with post-hoc comparisons using unpaired, two-sided Student’s t test 
(*P < 0.05). 
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Figure 2.33. Raw measurements of total neurite area (top panel) and total cell count (bottom 
panel) separated by each independent experiment. Mean measurements for each condition are 
displayed as the black horizontal lines.  
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Figure 2.34. Quantification of mean total cell counts from DAPI-staining of nuclei after drug 
treatments in three independent experiments. Each data point represents the mean measurement 
of 6-8 replicates from a single independent differentiation and expressed relative to vehicle 
controls. The coefficient of variation in vehicle-treated cells ranges from 2-9%. Raw values used 
to calculate the means are shown in Figure 2.33. Relative mean cell counts were tested for 
differences across drug conditions by one-way ANOVA; no significant differences were seen (P 
= 0.552). 
  
	 99	
DISCUSSION 
We identified multiple SNPs that implicate genes that may be relevant to MTA-induced sensory 
peripheral neuropathy, even though no SNP associations achieved genome-wide significance. 
Because the study scope focuses on sensory neuronal mechanisms involved in MTA-induced 
PN, seven independent SNP associations, whose nearest gene shows expression in human 
DRG38, were prioritized for in silico functional analysis to determine if the SNP lies in a 
potential regulatory genomic region. Three of the seven SNPs (rs74497159, rs10771973, 
rs11076190) had the strongest in silico evidence for predicted functional activity with previous 
reports linking their annotated genes (S1PR140,41, FGD49,14 and CX3CL142–44) to chemotherapy-
induced neurotoxicity.   
Among the three genomic regions identified from the primary meta-analysis, the highest-
ranking association based on P-values revealed the genomic region in chromosome 1 annotated 
to S1PR1, a gene that encodes for sphingosphine-1-phosphate receptor 1 (S1PR1). S1PR1 is a 
member of a G-coupled receptor family that is known for its roles in cell proliferation, migration 
and differentiation45. S1PR1 has been shown to be directly involved in mediating inflammatory 
responses through activation with its signaling ligand sphingosphine-1 phosphate (S1P), which 
has been targeted for autoimmunity diseases such as multiple sclerosis46, psoriasis47, and chronic 
inflammatory neuropathy48. Most notably in peripheral neurons, the S1P-to-S1PR1 axis has been 
associated with increased neuronal excitability49, reduction in neuronal growth through Rho 
GTPase signaling50, and increased hyperalgesia51 and other pain-like behaviors52–55. The 
association of S1PR1 G-coupled receptor signaling with Rho GTPase-mediated signaling in 
peripheral neurons is noteworthy since other genes involved in RhoA signaling have been 
previously implicated in genome-wide and sequencing studies of MTA-induced PN9–11,56–58. In 
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this study, the leading SNP annotated to S1PR1 had the highest-ranking association based on P-
values with a higher risk of peripheral neuropathy regardless of which MTA was administered. 
Additionally, this genomic region is encompassed in a functionally predicted enhancer region 
that may be acting directly on S1PR1 expression. Alongside these results and recent evidence 
highlighting S1PR1 as a drug target for prevention of chemotherapy-induced neuropathic pain in 
vivo40,41, functional studies were focused on investigating if modulating S1PR1 function in 
sensory neurons would protect against MTA-induced damage. 
Functional studies were performed using a human iPSC-derived sensory neuronal model 
that displays paclitaxel-induced neurodegeneration. The addition of the S1PR1 functional 
antagonist fingolimod (FTY720) to paclitaxel in these sensory neurons attenuates paclitaxel-
induced neurotoxicity with similar effect sizes as previous functional validation studies in 
cellular models of chemotherapy-induced neuronal damage 12,59–61. Additionally, functional 
antagonists of S1PR1 have consistently alleviated CIPN and other pain-like symptoms in vitro 
and in vivo40,41,62–64, and have led to recent phase I clinical trials investigating the use of 
fingolimod to prevent and treat chemotherapy-induced neuropathy (NCT03943498, 
NCT03941743).  While studies have also shown treatment with the S1PR1 antagonist W146 
mitigate paclitaxel-induced neuropathic pain40 and S1P-induced hypersensitivity and thermal 
sensitivity in vivo40,51, minimal effect is observed with W146 treatment in the current in vitro 
studies. Since previous studies have primarily focused on targeting S1PR1 in the spinal cord and 
have implicated its role as astrocyte-specific40,41, it is possible that a decrease in S1PR1 
expression from internalization and degradation65 is essential to mitigate the effects of paclitaxel 
in peripheral neurons. This need for degradation may explain why only blocking S1PR166 does 
not have the same pronounced protective effect. Interestingly, activation of S1PR3 may also be 
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involved in sensory neurite retraction, nociceptor excitability, and pain-like symptoms49,62,67. 
FTY720 has also been shown to bind to S1PR3 and other receptors65, although its functional 
activity is largely attributed to S1PR1 binding68. While expression of both S1PR1 and S1PR3 are 
known in primary DRG69 and iPSC-derived sensory neurons used in these studies (Figure 2.35), 
the exact role of these receptors in sensory peripheral neuropathy is not yet clear. These 
functional studies are the first step in understanding the role of S1PR1 signaling in peripheral 
sensory nociceptors under chemotherapy exposure and warrant further investigation to fully 
elucidate the role of sphingosine signaling in MTA-induced neuropathy.  
 
Figure 2.35 Sphingosphine-1-phosphate receptor expression in iPSC-derived sensory neurons 
compared with human DRG. Each data point represents raw DCt value for one experimental 
replicate. DCt values were calculated by normalizing the Ct value of each gene with the Ct value 
of actin (mean Ctactin,DRG = 15.90, mean Ctactin,iPSC-SN = 14.24). High DCt values correspond to 
low mRNA expression levels. 
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exclusively binds to CX3CR1 on lymphocytes. Paclitaxel treatment in pre-clinical models has 
been shown to increase levels of monocyte infiltration and inflammatory macrophage activation 
within peripheral nerves through CX3CL1-CX3CR1 crosstalk, releasing pro-inflammatory 
cytokines (TNF-a, IL-1b) and initiating peripheral neuropathic pain70. However, recent work by 
Yu et al. has demonstrated that nerve injury signals the local expansion of CX3CR1+ 
macrophages within the DRG itself and these DRG resident macrophages are responsible for 
neuropathic pain in vivo71.  Additionally, previous work suggests that increased recruitment of 
transcription factors (i.e., NF-kB) to the CX3CL1 promoter region is heightened in in vivo 
models of CIPN43. Since rs11076190 is in a predicted transcription factor binding site and 
potential promoter, it may modulate the contribution of CX3CL1 to this toxicity. Interestingly, 
rs223828 in complete LD with rs11076190 is located within an intronic transcription factor 
binding-rich region of CCL17, a gene that encodes for a small cytokine that has been shown to 
mediate granulocyte-macrophage-colony stimulating factor-dependent inflammatory pain that 
causes osteoarthritis72 and multiple sclerosis73.  While little is known about the interaction 
between CX3CL1 and S1PR1, their robust roles in signaling downstream cytokine release (e.g., 
TNF-a, IL-1b) that results in peripheral neuropathic pain suggests that regulation of 
neuroimmune interactions is important to the clinical symptoms in the periphery, and further 
validation may allow for interesting strategies to monitor CIPN. 
The intronic SNP rs10771973 of FGD4 was in the top SNPs from the meta-analysis and 
was the only variant identified in the previous GWAS in CALGB 40101 that remained in this 
meta-analysis9. Of note, FGD4 is a critical gene for peripheral nerve development74 and a known 
causal gene of Charcot-Marie-Tooth subtype 4H, which is characterized by distal muscle 
weakness, severe foot deformities, sensory weakness or loss, and gait instability75. With this 
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prior knowledge, it is conceivable that those harboring common genetic variation in FGD4 may 
be more susceptible to peripheral neurotoxicity upon drug exposure. Importantly, in another 
genetic association study in an independent population rs10771973 was linked with increased 
risk of paclitaxel dose reductions14. Investigation of the effects of paclitaxel on FGD4 function in 
peripheral sensory neurons warrants further investigation.  
While only three of the seven genomic regions associated with MTA-induced peripheral 
neuropathy have been previously recognized to play a role in CIPN, other genomic regions may 
also be important for unveiling biological mechanisms underlying this toxicity. rs17076837 and 
rs2188156 annotate to SLITRK1 and SEPT5, respectively, which are highly expressed in human 
DRG and are associated with neuronal function. SLITRK1 has been shown to be involved in 
regulating synaptic formation after axonal growth to its target area in hippocampal neurons76 
while SEPT5 is a member of a highly conserved family of GTP binding proteins that regulates 
cytoskeletal reorganization in neurons77. However, there is limited evidence that these intergenic 
SNPs are enriched for regulatory activity to these annotated genes. In contrast, rs2060717 lies in 
a highly predicted promoter site within an intronic region of CALU, a gene that encodes for 
calcium-binding protein calumenin which localizes to the endoplasmic reticulum with potential 
roles in early neuronal development78. Lastly, rs9623812 lies in a potential enhancer site within 
an intronic region of SCUBE1, encoding for a cell surface glycoprotein that is secreted during 
brain injury79. Further studies are needed to understand the roles of these genes in sensory 
neurons and may lead to novel mechanisms of MTA-induced PN. 
While this pharmacogenetic study using human genomic and cellular data has identified 
potential genes that have a translatable relevance to the CIPN phenotype, there are several 
limitations. Although a total of 1,324 samples from the discovery cohorts was used in the meta-
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analysis, the pharmacogenetic study presented is still insufficiently powered and increasing 
sample size may provide a more robust analysis. The main limitation is genetic validation of our 
top-ranking SNPs. None of the top-ranking SNPs (P < 10-5) from our meta-analysis were 
replicated in the taxane-treated ECOG-5103 European cohort57 or in the UK BioBank (Tables 
2.5 and 2.6). In the case of ECOG-5103, paclitaxel treatment is different from both CALGB 
40502 and CALGB 40101 and this sample was also limited by size. While the UK BioBank is 
proving to be a useful resource for replication of genetic associations with common phenotypes, 
the largest number of drug-induced polyneuropathy cases identified was 122 subjects for two 
ICD9 codes classified as “polyneuropathy due to drugs” and “polyneuropathy due to toxic 
agents”.  
Table 2.5 Results from candidate SNP association analysis in ECOG-5103 replication European 
cohort (n=1,348) 
SNP* Chr Allelesa Gene SNP (r2)† MAF Effect P 
rs12402160 1 C>T 178 kb 3’ of 
S1PR1 
rs74497159 (0.7) 0.100 -0.283 0.0098 
rs223828 16 T>C intronic 
region of 
CCL17 
rs11076190 (1.0) 0.051 -0.216 0.098 
rs2060717 7 G>A intronic 
region of 
CALU 
– 0.059 0.110 0.41 
rs1894716 22 G>A intronic 
region of 
SCUBE1 
rs9623812 (0.97) 0.305 -0.045 0.49 
rs11831099 12 C>T intronic 
region of 
FGD4 
rs10771973 (0.98) 0.316 0.028 0.65 
SNP, single nucleotide polymorphism; Chr, chromosome; MAF, minor allele frequency 
*SNPs listed are LD-pruned to show the top-ranking SNP by P value of replication analysis 
aAlleles are denoted Ref>Alt 
†Linkage disequilibrium r2 with SNPs from primary meta-analysis (Table 2.3) 
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Table 2.6 Results from candidate SNP association analysis in UK BioBank replication (n=122) 
SNP* Chr Allelesa Gene SNP (r2)† MAF Effect P 
rs76464064 7 C>T 107 kb 3’ of 
SUGCT 
rs78017515 (0.96) 0.074 0.843 0.044 
rs74497159 1 T>G 168 kb 3’ of 
S1PR1 
–  0.072 0.653 0.092 
rs57940640 16 G>A intronic region of 
CNGB1 
– 0.069 -0.416 0.094 
rs10844261 12 A>G intronic region of 
FGD4 
rs10771973 (0.93) 0.302 0.261 0.130 
rs223828 16 C>T intronic of CCL17 rs11076190 (1.0) 0.047 -0.570 0.211 
rs2342796 8 T>C 7.5 kb 5’ of 
ZFPM2 
rs2342791 (0.77) 0.165 -0.180 0.404 
rs9623812 22 A>T intronic region of 
SCUBE1 
– 0.329 -0.116 0.454 
rs13168251 5 T>G 718 kb 3’ of 
LOC100129716 
– 0.099 0.200 0.459 
rs77526807 9 G>T 39 kb 3’ of 
C9orf106 
– 0.064 0.252 0.461 
rs10281585 7 T>G 75 kb 3’ of 
SUGCT 
rs78777495 (0.91) 0.115 0.165 0.509 
rs2342780 8 A>T 68 kb 5’ of 
ZFPM2 
– 0.070 -0.197 0.547 
rs1083337 6 G>A 490 kb 5’ of 
ADGRB3 
rs777619 (0.99) 0.201 0.105 0.586 
rs2060717 7 G>A intronic region of 
CALU 
– 0.051 0.120 0.741 
rs17076837 13 C>G 382 kb 3’ of 
SLITRK1 
– 0.120 -0.073 0.748 
rs6788186 3 C>T 696 kb of 3’ 
ZBBX 
– 0.268 0.048 0.772 
SNP, single nucleotide polymorphism; Chr, chromosome; MAF, minor allele frequency 
*SNPs listed are LD-pruned to show the top-ranking SNP by P value of replication analysis 
aAlleles are denoted Ref>Alt 
†Linkage disequilibrium r2 with SNPs from primary meta-analysis (Table 2.3) 
 
The other main limitation is the use of NCI-CTCAE grading for phenotyping peripheral 
neuropathy events, which has been shown to underestimate the progression of neuropathy 
symptoms80,81 and embody inconsistency in scale interpretation82. It is likely that phenotyping a 
combination of patient-reported and physician-reported outcomes will yield more comprehensive 
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information. Lastly, our functional studies were limited to studying effects of S1PR1 in sensory 
neurons and did not investigate potential cross-talk between neurons and other cell types in the 
periphery. As CX3CL1 and S1PR1 both play predominant roles in peripheral lymphocytes, it is 
possible that their effects on paclitaxel-induced damage to peripheral nerves are initiated by 
external cues from other cell types. This phenomenon is true with FGD4, where the interplay of 
the frabin (FGD4)-Cdc42 Rho GTPase axis in Schwann cells causes peripheral nerve 
demyelination in CMT4H83. Additionally, other genes identified by this genome-wide study 
(e.g., CALU, SCUBE1) not functionally explored also warrant further studies to investigate their 
roles in peripheral neurons, which may reveal interesting mechanisms underlying MTA-induced 
neuropathy.  
In conclusion, this genome-wide association meta-analysis has identified potential 
genetic markers of MTA-induced peripheral neuropathy. This pharmacogenetic study highlights 
the importance of S1PR1 receptor signaling from a genome-wide discovery analysis using 
clinical samples and functional validation using human iPSC-derived sensory neurons. Of note, 
S1PR1 signaling functionally intersects between both Rho-GTPase signaling and 
neuroinflammation, which have been well-documented to play roles in MTA-induced peripheral 
neuropathy.  Further genomic and functional validation of sphingosine-1-phosphate signaling 
may lead to a novel and exciting strategy for prevention and/or treatment of chemotherapy-
induced neuropathy. 
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Chapter 3:  Exome Sequencing in CALGB 40502 Reveals Genes in Actin Dynamics 
Associated with Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy  
 
INTRODUCTION 
 
The main dose-limiting non-hematological toxicity for patients undergoing microtubule targeting 
chemotherapy is sensory peripheral neuropathy (PN). Understanding patient susceptibility to 
developing drug-induced SPN has the potential to guide selection of chemotherapies, optimize 
dose, manage neurotoxicity, and improve overall quality of life. Previous genome-wide studies 
on microtubule targeting agent (MTA)-induced peripheral neuropathy have been primarily 
focused on identifying associations of the neurotoxicity with common genetic variants due to the 
high incidence rate, where such studies are statistically powered to discover common variants 
with modest effect sizes (Chapter 1, Table 1.3).  
Human genetic studies in this field have not yet fully explored the importance of multiple 
rare variants involved in this common complex phenotype, although it is recognized that the 
majority of functional variability with large effects in complex traits lie within rare variation1,2. 
Collectively, the known clinical factors and identified common genetic variants associated with 
MTA-induced SPN have not accounted for the high incidence rate, suggesting there are still 
undiscovered predictors contributing to the development of the toxicity. A previous polygenic 
heritability analysis on common SNPs suggests genes critical to axon outgrowth processes are 
important drivers of paclitaxel-induced sensory peripheral neuropathy (PN)3; however these gene  
have not been fully captured with conventional GWAS and may lie within rare variation.  
Fortunately, recent genomic technological advances have allowed the opportunity to interrogate 
these rare variants with large effect sizes, which are likely to have more clinical utility and lead 
to novel insights on the underlying mechanism behind the development of MTA-induced 
toxicity. A few targeted sequencing studies on MTA-induced PN have supported involvement of 
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gene pathways previously implicated in GWA studies. The Beutler et al. 20144 study identified 
patients with genetic variations in ARHGEF10, a Charcot-Marie-Tooth (CMT) disease gene 
essential for Rho GTPase activity during neuronal extension and morphogenesis, were more 
susceptible to chemotherapy-induced peripheral neuropathy (CIPN); a finding replicated in an 
independent cohort5. Consistent with some initial candidate gene studies, Apellániz-Ruiz et al. 
demonstrated patients with rare variants in drug metabolizing gene CYP3A4 had reduced enzyme 
activity and higher probability of paclitaxel modifications due to severe neuropathy events6. 
However, another study7 focusing on targeted sequencing in coding regions in EPHA genes, 
paclitaxel pharmacokinetic genes, and CMT genes found only low-frequency variants in 
EPHA5/6/8 contribute to paclitaxel-induced neuropathy.  
While targeted sequencing corroborates gene associations previously implicated in 
GWAS, whole exome sequencing provides an unbiased approach to discovering novel genes 
associated with MTA-induced PN. However, only a few sequencing studies have utilized this 
exome-wide approach. The first whole exome sequencing study on MTA-induced PN further 
underscored the connection with rare congenital peripheral neuropathies, discovering association 
of rare deleterious variants in CMT gene SBF2 to taxane-induced peripheral neuropathy8. The 
second exome sequencing study on vincristine-induced peripheral neuropathy implicated genes 
related to mitochondrial protein synthesis, neuronal migration, and transcriptional regulation 
(i.e., MRPL47, SYNE2, BAHD1)9.  
Building on these exome-wide studies, our study is motivated to further extend the 
discovery from common variants to include low-frequency and rare variants that may influence 
susceptibility to MTA-induced SPN. More specifically, our study uses a gene-based approach to 
identify novel genes that may influence the underlying mechanisms involved in sensory neuronal 
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damage under MTA exposure, manifesting in risk of chemotherapy-induced peripheral 
neuropathy.  
 
MATERIALS AND METHODS 
 
Participants 
All study participants were enrolled in Cancer and Leukemia Group B (CALGB) 40502, a 
randomized three-arm phase III trial conducted to determine whether nanoparticle albumin-
bound (nab) paclitaxel or ixabepilone is superior to paclitaxel as first-line therapy for patients 
with advanced breast cancer. CALGB 40502 was open from October 2008 through November 
2011, enrolling a total of 799 subjects. Eligibility criteria for enrollment has been previously 
described10. CALGB is now part of the Alliance for Clinical Trials in Oncology. All patients 
provided written informed consent for both the treatment and companion protocols that met state, 
federal, and institutional guidelines. Patient characteristics of entire CALGB 40502 cohort and 
those consented into the pharmacogenetic study have been previously described (Chapter 2, 
Results Table 2.2).  
 
Definition of peripheral neuropathy phenotype 
Adverse events, including chemotherapy-induced peripheral neuropathy (PN), are graded 
according to the NCI Common Terminology Criteria for Adverse Event (NCI-CTCAE), defining 
the range of severity of neuropathy cases as Grade 0-5. Because the incidence of the toxicity is 
dependent on cumulative drug exposure, sensory peripheral neuropathy was assessed with a 
dose-to-event phenotype. A microtubule-targeting agent (MTA)-induced sensory peripheral 
neuropathy event was defined as the cumulative MTA dose (mg/m2) to first instance of grade II 
or higher PN event and used as the primary endpoint in analyses. For patients who experience no 
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neuropathy event, the cumulative chemotherapy dose was censored at the time of removal from 
study, accounting for competing risks to developing a neuropathy event. Characteristics of 
cumulative dose-to-first instance of grade 2 or higher PN phenotype was previously described 
(Chapter 2, Results). 
 
Whole Exome Sequencing 
From those enrolled in CALGB 40502, a total of 635 consented patients with DNA samples were 
available for whole-exome sequencing. Genomic DNA extracted from blood samples was 
provided by the Alliance Pathology Coordinating Office, and sequencing was performed at the 
UCSF Genomics Core Facility. Probes were designed to target the whole exome and additional 
intronic regions from selected candidate genes for a total target size of 90 Mb (64 Mb standard 
exome with 26 Mb custom regions). Candidate genes were chosen based on existing mechanistic 
information on sensory peripheral neuropathy, including genes involved in taxane metabolism 
and transport, genes associated with inherited peripheral neuropathies, genes previously 
identified in Gene Ontology (GO) terms related to axon outgrowth, and additional genes curated 
from a review of literature on chemotherapy-induced peripheral neuropathy; a total of 242 
unique genes were selected (Table 3.1). Variants annotated to 3’ and 5’ untranslated regions 
(UTRs), downstream and upstream regions, intergenic regions, and intronic regions of the 
candidate genes were additionally captured along with those captured from the standard exome. 
Sequencing libraries were generated using the KAPA HyperPrep Kits (Illumina) and 
captured enrichment of custom target regions using SeqCap EZ Exome Plus Kit (Roche 
NimbleGen). Enriched libraries were sequenced on the HiSeq4000 System (Illumina) using 
paired-end 150 bp runs. For a random set of 150 sequenced samples, a mean target coverage of 
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83X (range: 4.52-176.80X) was achieved, where 99% of samples exhibited at least 20X coverage 
over 80% of the target.  
Table 3.1 Candidate genes in targeted custom capture 
Genes Description Count 
ABCB1, ABCC1, ABCC2, ABCG2, 
CYP1B1, CYP2C8, CYP3A4, CYP3A5, 
MAP2, MAP4, MAPT, NR1l2, 
SLCO1B3 
Paclitaxel PKPD pathway 13 
SETX, ARHGEF10, ATL1, BSCL2, 
CCT5, CTDP1, DCTN1, EGR2, DNM2, 
FAM134B, FGD4, FIG4, GAN, GARS, 
GDAP1, GJB1, HSPB1, HSPB8, 
IGHMBP2, IKBKAP, KIF1B, LITAF, 
LMNA, MFN2, MPZ, MTMR2, 
NDRG1, NEFL, NGF, NTRK1, 
PLEKHG5, PMP22, PRPS1, PRX, 
RAB7A, SBF2, SEPT9, SH3TC2, 
SLC12A6, SOX10, SPTLC1, SPTLC2, 
YARS, WNK1 
Inherited peripheral neuropathy 
genes 
44 
NRP2, SEMA3F, SEMA3B, PLXNC1, 
DSCAM, RTN4, SEMA4B, RTN4R, 
ALCAM, SEMA5A, GOLGA4, RYK, 
SEMA6C, ULK2, TPBGL, MT3, 
PLXND1, SHTN1, SEMA3D, SEMA4F, 
NTN1, L1CAM, SLIT2, SEMA6D, 
TWF2, SEMA3E, SEMA4D, SLC9A6, 
PLXNA4, SEMA6A, SEMA4A, 
SEMA6B, VEGFA, PPP3CB, RNF6, 
ULK1, SEMA7A, MACF1, SLIT3, 
SLIT1, PLXNA2, PLXNA1, CDKL5, 
SEMA3C, MEGF8, MAPT, BCL11A, 
PLXNB1, SEMA4G, SEMA3G, 
SEMA3A, CDK5, NLGN3, USP9X, 
SEMA4C, RUFY3, LIMK1, ISLR2, 
NRP1, SEMA5B, PLXNA3, CYFIP1, 
DPYSL2, MGLL, TTL, AMIGO1, 
METRN, EPHA4, EPHB3, GDI1, 
BDNF, OMG, ROBO1, MARK2, 
LINGO1, PLXNB2, ARHGEF1, 
NRCAM, ROBO2, LRRC4C, CHN1, 
CLASP2, MAG, LRP4, NGFR, SKIL, 
SSH1, OLFM1, THY1, PLXNB3, SSH3, 
APOE, PTPRO, NTRK2, CTTN, 
SIPA1L1, SSH2, ABL1, KIF13B, NGF, 
RHOA, FGF13, PTEN, FEZF2, 
ARHGDIA, DNM2, DCC 
Genes from Gene Ontology 
Axonogenesis pathway 
107 
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Table 3.1 (cont.) Candidate genes in targeted custom capture 
Genes Description Count 
TRPA1, TRPV1, TRPV4, CCR2, 
CCL2, SIGMAR1, MORN4, SLC1A3, 
SLC1A1, SLC1A2, GSK3B, MTOR, 
AKT1, CX3CR1, PRKCB, PRKCD, 
PRKCE, CCL3, P2X7R, TNF, 
ROCK1, KCNB2, TRPM8, CNR2, 
TLR4, MYD88, ADORA3, 
CACNA2D1, CAPN1 
Literature on animal peripheral 
neuropathy studies 
29 
SCN4A, PRX, ARHGEF10, IKBKAP, 
NEFL, NGFR, CTSS, CTLA4, 
PSMB1, DYNC1I1, TCF4, 
SERPINE1, ADRB2, ID3, CYP2C9, 
CAMKK1, SLC10A2, NFATC2, 
TAC1, FOXC1, ITGA1, CYP2C8, 
TUBB2A, RFX2, EPHA4, EPHA5, 
EPHA6, LIMK2, XKR4, ACTG1, 
CAPG, ABCB1, CCNH, ABCG2, 
ABCG1, GPX7, ABCC4, TUBB2A, 
ARHGEF10, CEP72,VAC14, FZD3, 
EPHA5, FGD4, DNM1L, ERCC1, 
ERCC2, ABCA1, FANCD2, RWDD3, 
TECTA, FZD3, NDRG1, FGD4, 
PITPNA, CAND1, CACNB2, XKR4, 
BCL6, CYP2C8, ABCB1, ABCC2, 
CYP1B1, ERBB4, LIMK2, MISP, 
SHROOM3, GPX7, ABCC4, BCR, 
AIPL1, FCAMR, WLS, DPP6, 
DIDO1, ATP1A2 
Literature on human peripheral 
neuropathy studies 
75 
 
Quality Control 
Sequencing reads were processed on an internal pipeline in accordance to GATK Best Practices 
Workflows on germline short variant discovery (version 2018Jan07). In brief, sequencing reads 
were mapped to hg38 reference genome using Burrows-Wheeler Aligner (BWA-MEM v0.7.15). 
Aligned reads were marked for duplications using Picard (version 2.18.27-1-g21ad30b-
SNAPSHOT) and recalibration of base quality scores were performed using GATK (v4.0.12.0). 
Variant discovery was conducted on all samples using GATK v4.0.12.0 HaplotypeCaller in 
GVCF mode to allow for efficient joint genotyping of all samples (GATK v4.0.12.0 
GenotypeGVCFs) and resulted in a single variant call format (VCF) file. Variants were initially 
filtered for high quality calls, excluding variants with VQSLOD score corresponding to the truth 
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sensitivity threshold of 99.90% for indels and 99.80% for SNPs (GATK v4.0 0.12.0 VQSR) and 
variant calls were set to null if read depth (DP) < 10 and genotype quality (GQ) < 20. Only 
variants with a single nucleotide reference allele were considered in the discovery analysis. 
Concordance checks between sequencing variants that overlapped with genotyped 
variants on OmniExpressExome array (Illumina) were conducted; samples were confirmed to 
have concordance rates > 90%. Samples with low mean read depth (<10X; n = 4), per-sample 
call rate < 90% (n = 3), heterozygosity estimation beyond three standard deviations (n = 2), and 
high degree of relatedness due to plating errors (n = 2) were excluded. Sex check was performed 
on genotyped data and excluded three additional samples. Principal component analysis (PCA) 
was performed on these samples using genotyped data, and the first 3 PC vectors were used to 
adjust for population stratification in the discovery analysis. Among these subjects that passed 
sample quality control, a total of 612 subjects had both genotype and phenotype information, 
which were further used as the discovery cohort in this analysis. After sample exclusion, variants 
were excluded if > 10% missing data among the discovery cohort, significant deviation from 
Hardy-Weinburg equilibrium (P < 10-6), and monomorphic in those with reported PN events 
within each stratum. A summary of sample and variant quality control is displayed in Figure 3.1, 
and sample metrics of the discovery cohort are tabulated in Table 3.2. 
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Figure 3.1 Summary of sample and variant quality control pipeline. 
 
Table 3.2 Summary of sample quality on discovery cohort (N = 612). 
 Mean Range Total 
Call rate† 95.09 0.901-0.975 – 
Read depth† 66.13 32.737-156.206 – 
Heterozygosity† 0.0384 -0.273-0.192 – 
Ti/Tv ratio 2.13 1.93-2.25 2.32 
Nonsynonymous/synonymous ratio 0.947 0.911-0.978 1.4 
All variants 4,608,106 1,858,968-12,431,101 1,351,075 
Novel variants (absent from dbSNP 150) 105,725 99,367-126,219 191,129 
Singletons 144,661 121,811-175,517 634,352 
†Estimated on samples after filtering variant calls with DP > 10 and GQ > 20 
 
The remaining variants were annotated with Ensembl gene names and functional 
consequences using ANNOVAR (v2018APR16). Predictions of functional impact for variants 
were obtained from bioinformatic databases, including SIFT, PolyPhen2-HDIV, Mutation 
Assessor, REVEL, CADD, and GERP++. Protein coding variants were defined as “exonic”, 
“exonic;splicing”, or “splicing” variants by Ensembl annotation. Nonsynonymous variants with 
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predicted deleterious state in at least two (out of six) databases (Table 3.3), frameshift deletions, 
stop gain variants, stop loss variants, and all splicing variants were considered in the genome-
wide gene-based analysis (Table 3.4). All noncoding variants annotated to the candidate genes 
were used in the candidate gene-based analysis. 
Sequence kernel association tests (SKAT) were used to evaluate the aggregated effects of 
two variants types: 1) rare (MAF ≤ 1%) and 2) low frequency variants (MAF 1-5%) in each 
gene. Candidate gene analyses only included variants annotated to any of the 242 candidate 
genes (Table 3.1). Each association test was performed with a Cox regression analysis using the 
cumulative dose-to-first instance of grade 2 or higher PN event as the phenotype. All tests were 
stratified by treatment arm and adjusted for age. Associations with Bonferroni-adjusted P values 
< 0.05 were considered statistically significant. All P values reported are unadjusted.  
 
Statistical analyses 
Gene-based SKAT analyses were performed using the seqMeta11 and survival12 packages 
within the R (v3.5.3)13 statistical environment. 
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Table 3.3 Bioinformatic databases used for functional prediction and corresponding outcomes of 
predicted variant function 
Functional prediction 
database 
Possible prediction outcomes Deleterious definition 
SIFT Tolerated (T), deleterious (D) D 
Polyphen2-HDIV Unknown (U), benign (B), 
probably damaging (D), 
possibly damaging (P) 
D, P 
Mutation Assessor Neutral (N), low (L), medium 
(M), high (H) 
M, H 
REVEL score† 0 – 0.996 > 0.5 (score at which 75% 
variants deleterious and 10% 
neutral) 
CADD phred score† 0.001 - 72 ≥ 10 (predicted in top 10% 
deleterious variants) 
GERP++ score† -12.30 – 6.17 > 0 (positive scores are 
considered highly-conserved 
positions) 
†Range of scores observed from annotation of all variants 
 
Table 3.4 Summary of gene-based association tests performed 
Analysis type Variant type Criteria 
Genome-wide, 
exonic regions 
Rare variant* Coding variants: 
• At least 2/6 databases with deleterious label 
• Stop gain and stop loss variants 
• Frameshift mutations 
• Splicing variants 
Low-frequency 
variant† 
Coding variants: 
• At least 2/6 databases with deleterious label 
• Stop gain and stop loss variants 
• Frameshift mutations 
• Splicing variants 
Candidate gene 
regions 
Rare variant* Noncoding variants 
Low-frequency 
variant† 
Noncoding variants 
*Rare variants defined by minor allele frequency ≤ 1% in discovery cohort, which included singletons (alternate 
variant allele count = 1) 
†Low-frequency variants defined by minor allele frequency of 1-5% in discovery cohort 
Gene-based association analysis 
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RESULTS 
Among the 799 individuals randomized to CALGB 40502, 635 subjects were sequenced on the 
Illumina HiSeq4000 using the Roche SeqCap EZ Exome Plus library, targeting whole exomes 
with additional custom candidate gene regions. Patient characteristics of the pharmacogenetics 
and clinical trial population of CALGB 40502 have been previously described (Chapter 2, 
Results Table 2.2). In brief, the pharmacogenetic discovery cohort used in this analysis is 
proportional to the entire clinical trial cohort in regards to patient characteristics, including age, 
self-reported race/ethnicity, prior taxane status, and tumor subtype. After sample quality control, 
a total of 612 subjects and 1,155,976 variants were isolated for the discovery analyses (Figure 
3.1). The cumulative incidence of PN in each treatment arm of CALGB 40502 was previously 
described (Chapter 2, Results Figure 2.5). From the discovery cohort, a total of 312 patients had 
a reported grade 2 or higher PN event, and cumulative doses were defined at time of event. The 
remaining 300 patients were censored at the time they were removed from the trial for 
progression/death, other adverse events, other complicating disease, patient withdrawal, and 
other reasons. Only four of the 300 completed treatment per protocol and were censored at 
therapy completion.   
To investigate gene-based effects on cumulative risk of chemotherapy-induced peripheral 
neuropathy in this cohort, a Cox regression model incorporated into the SKAT tests was 
performed to calculate the aggregated contribution of rare or low frequency deleterious coding 
variants from each gene (Table 3.4). None of the gene associations reached genome-wide 
significance in either the low-frequency or rare variant analysis, although there are some top-
ranking genes based on P value that were further investigated. Because the goal of these 
discovery analyses is focused on understanding the biology of the underlying sensory neuron 
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toxicity, we further filtered for genes with P < 10-4, an expression level of at least 3 FPKM in 
human dorsal root ganglion (DRG)14 and a previously described function in neurogenesis or 
associations to neuropathy (Table 3.5); only two genes met these criteria, PRDM16 and SHC4. 
Since the role of IFT46 is primarily characterized in ciliated sensory neurons in C. elegans 
without a clear translation to human neurons, it was not considered further. While PEAR1 and 
TRIOBP did not reach the same association P value threshold, these genes are highly expressed 
in human DRG with evidence for involvement in sensory neuron excitability and axonal 
extension. All variants aggregated from these four genes were missense exonic variants with 
minor allele count (MAC) ranging from 4-50 (Table 3.6).  
Among the identified genes in the rare variant analysis, PRDM16 was explored for 
further support of association with PN. The rare variant rs371654192, which lies in exon 9 of 
PRDM16, is predicted to be deleterious in five of six in silico prediction databases (Table 3.6). In 
CALGB 40502, there was a trend toward a higher proportion of reported PN events for patients 
harboring rs371654192 compared to those with reference allele (paclitaxel: 0.47 vs. 1, nab-
paclitaxel: 0.54 vs. 0.67, ixabepilone: 0.51 vs. 0.50) (Figure 3.2), although these estimates are 
interpreted with caution considering the small number of subjects harboring this rare variant. 
Additional bioinformatic analysis using ENCODE data (UCSC Genome Browser) revealed this 
SNP lies within a regulatory element for early growth response 1 (EGR-1), a binding site for 
transcription factor enhancer of zeste homolog 2 (EZH2), and a DNaseI hypersensitivity site.  
Subjects with the variant had 40-50% of the median cumulative MTA dose to first instance of 
PN when compared to those without the variant.  
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Table 3.5 Top gene associations ranked by P value from genome-wide tests aggregating effects 
across rare and low-freqency variants 
Analysis Gene Gene Description P Cumulative 
MAF 
No. 
SNPs 
Human 
DRG† 
Literature 
PMID 
Rare 
variants 
OR8B2 Olfactory Receptor 
8B2 
6.12E-05 0.0090 1 0.00 – 
PRDM16 PR Domain 
Containing 16 
1.74E-04 0.0065 1 6.17 29779941, 
22197833, 
19050759 
PARP15 Poly(ADP-Ribose) 
Polymerase Family 
Member 15 
6.99E-04 0.0075 1 0.41 – 
IFT46 Intraflagellar 
Transport 46 
9.08E-04 0.0033 1 11.13 24339792 
MGAT4B Alpha-1,3-
Mannosyl-
Glycoprotein 4-
Beta-N-
Acetylglucosaminyl
transferase B 
0.00107 0.0098 2 28.70 – 
Low 
frequency 
variants 
USP6 Ubiquitin specific 
peptidase 6 
3.57E-04 0.026 1 1.62 31841517 
SHC4 Src Homology 2 
Doman-Containing-
Transforming 
Protein C4 
2.67E-04 0.015 1 12.80 21117147, 
28213521, 
31823725 
C7orf50 Chromosome 7 
Open Reading 
Frame 50 
0.00120 0.014 1 28.36 – 
PEAR1 Platelet Endothelial 
Aggregation 
Receptor 1 
0.00174 0.085 4 20.94 31992767 
TRIOBP TRIO And F-actin 
Binding Protein 
0.00182 0.12 5 15.87 25065758, 
28832620, 
25333879 
†Human DRG RNA-Seq expression levels from Flegel et al.14 
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Table 3.6 Characterization of deleterious variants aggregated in genes of interest from genome-
wide analysis 
Variant 
Name 
Gene Ref>Alt MAC Variant 
type 
Functional 
consequence* 
Deleterious 
labels  
rs371654192 PPRDM16 G>C 8 missense  Exon 9, R824P S, P, M, C, G  
rs16961728 SHC4 T>G 18 missense  Exon 8, Q400H MA, C  
rs147639000 PEAR1 G>A 28 missense  Exon 10, D343N C, G  
rs1952294 PEAR1 C>T 13 missense  Exon 8, S234P C, G  
rs41299597 PEAR1 C>G 26 missense  Exon 19, S802C P, C, G 
rs77795865 PEAR1 C>T 37 missense  Exon 11, S381F S, P, MA, C, G 
 rs142024473 TRIOBP C>T 44 missense  Exon 7, A660V MA, C, G 
rs150690007 TRIOBP G>A 13 missense  Exon 7, R745K S, G  
rs193043234 TRIOBP C>G 21 missense  Exon 7, P1030R S, P, MA, C, G  
rs41296243 TRIOBP C>T 24 missense  Exon 7, S826L S, C, G  
rs41302575 TRIOBP C>G 50 missense  Exon 7, T817S P, C, G  
MAC: minor allele count, MA: MutationAssessor, P: PolyPhen2, S: SIFT, C: CADD, G: GERP++ 
*Based on longest transcript in Ensembl annotation 
 
 
Figure 3.2 Cumulative dose to first instance of PN event for those with and without alternate 
alleles in rare variants rs371654192/PRDM16 and rs16961728/SHC4. The median cumulative 
doses to first instance of grade 2 or higher PN event and number of patients with and without a 
reported grade 2 or higher PN event in each category are displayed below the boxplots. 
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From the low-frequency variant analysis, a similar increase in PN event rate was 
observed in those harboring the SNP rs16961728 in exon 8 of SHC4 (Figure 3.2) in both the nab-
paclitaxel and ixabepilone arms but not in the paclitaxel arm; the median doses to grade 2 PN 
were largely unchanged between carriers and non-carriers of rs16961728. Bioinformatic analysis 
on rs16961728 shows predicted disruption in the regulatory motif for autoimmune regulator 
(AIRE) with regulatory histone promoter, histone enhancer, and DNase marks in various tissues 
(HaploReg v4.1). Four missense exonic SNPs (rs147639000, rs1952294, rs41299597, 
rs77795865) were evaluated in the gene association test for PEAR1. Subjects with at least one 
low-frequency variant in PEAR1 have a higher incidence of grade 2 or higher PN events 
(paclitaxel: 0.44 vs 0.71, nab-paclitaxel: 0.52 vs 0.69, ixabepilone: 0.48 vs 0.63) with no 
significant difference in median cumulative MTA exposure between carriers and non-carriers of 
a PEAR1 variant (Figure 3.3). rs147639000 was found to be in high linkage disequilibrium with 
intronic SNPs of ARHGEF11 (HaploReg v4.1). One of these SNPs, rs41299597, is significantly 
associated with expression quantitative trait loci for multiple genes, suggesting this variant may 
regulate expression of PEAR1 (whole blood tissue), ARHGEF11 (thyroid tissue), and SLC25A44 
(tibial nerve) (GTEx). The other SNPs are also annotated with histone enhancer and promoter 
marks in various tissues and predicted to disrupt regulatory motifs for important neuron 
transcriptional factors including neuron-restrictive silencer factor (NRSF) (HaploReg v4.1). For 
TRIOBP, five missense SNPs (rs142024473, rs150690007, rs193043234, rs41296243, 
rs41302575) were considered in the gene association test. Patients in the ixabepilone arm and to 
a lesser extent in the nab-paclitaxel arm harboring at least one low-frequency variant in TRIOBP 
tolerated higher median cumulative doses with similar rates of PN events (Figure 3.3). 
Bioinformatic analysis supports disruption of protein regulatory motifs important for 
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neurogenesis, including early growth response protein 1 (EGR-1) and glucocorticoid receptor 
(GR), by the rs150690007, rs41296243, and rs193043234 variants. The SNPs rs41296243 and 
rs41302575 are also associated with expression quantitative trait loci for multiple genes 
including SLC16A8 in tibial nerve tissue (GTEx).  
 
 
Figure 3.3 Cumulative dose to first instance of grade 2 or higher PN event in each treatment arm 
for those with and without deleterious low-frequency variants in PEAR1 (left) and TRIOBP 
(right). The median cumulative doses to first instance of grade 2 or higher PN event and number 
of patients with and without a reported grade 2 or higher PN event in each category are displayed 
below the boxplots. 
 
 
For candidate gene analysis, none of the gene-based associations reached statistical 
significance (unadjusted threshold, P < 10-4) (Table 3.7). Among the top-ranking genes in both 
low frequency and rare variant candidate gene analyses, only one gene (ACTG1) reached a 
threshold of P value < 0.01 and has the highest expression in human DRG. Of the 10 SNPs, one 
SNP (rs1140892) is a splicing variant, three SNPs (rs117809695, rs75355043, rs76770927) are 
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intronic variants, five SNPs (rs1139408, rs1139414, rs11549167, rs55902924, rs55978907) are 
located in the 3’UTR, and one SNP (rs1139403) is located in the 5’UTR (Figure 3.4). Subjects in 
the nab-paclitaxel arm harboring at least one low-frequency variant in ACTG1 trended towards a 
higher median cumulative MTA doses, but this was not consistent in the other two treatment 
arms. The proportion of patients developing PN was also similar in carriers and non-carriers in 
each study arm. However, SNPs in ACTG1 (rs76770927, rs1139408) have been linked to 
disruption in regulatory binding motifs of NRSF and GR, similarly to those in PEAR1 and 
TRIOBP, respectively. 
 
Table 3.7 Top-ranking gene associations (P < 0.05) from candidate gene-based association tests 
using rare and low-frequency variants. 
Analysis Gene Gene 
Description 
P Cumulative 
MAF 
No. SNPs Human 
DRG† 
Rare variant LMNA Lamin A/C 0.012 0.11 15 124.04 
PRX Periaxin 0.016 0.069 8 263.49 
ADORA3 Adenosine A3 
Receptor 
0.019 0.0065 2 6.84 
NR1l2 Pregnane X 
Receptor 
0.046 0.169 23 0.02 
NGFR Nerve Growth 
Factor Receptor 
0.047 0.033 6 325.76 
EPHA4 Ephrin Type-A 
Receptor 4 
0.047 0.84 134 0.84 
Low-
frequency 
variant 
ACTG1 Actin Gamma 1 0.0065 0.26 10 1426.86 
SLC1A3 Excitatory 
Amino Acid 
Transporter 1 
0.018 1.03 41 5.66 
CCT5 Chaperonin 
Containing 
TCP1 Subunit 5 
0.027 0.26 13 36.34 
CYP3A4 Cytochrome 
P450 3A4 
0.028 0.45 19 0.04 
SEMA6D Semaphorin 6D 0.034 13.67 611 10.86 
SHTN1 Shootin 1 0.034 5.35 243 5.85 
†Human DRG RNAseq expression levels from Flegel et al.14 
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Figure 3.4 Cumulative dose to first instance of grade 2 or higher PN event in each treatment arm 
for those with and without low-frequency noncoding variants in ACTG1 (left). The median 
cumulative doses to first instance of grade 2 or higher PN event and number of patients with and 
without a reported grade 2 or higher PN event in each category are displayed below the boxplots. 
Annotation of low-frequency variant types aggregated in ACTG1 from the candidate gene-based 
analysis is shown in the inset (right).  
 
From the top-ranking candidate gene associations, our results also highlight CYP3A4 and 
PRX, which have been previously implicated with CIPN in whole exome sequencing studies. 
Among the 19 low-frequency variants evaluated in CYP3A4, 17 SNPs are intronic variants, and 
two SNPs (rs28371763, rs28988604) are located in the 3’UTR (Figure 3.5). Carriers of CYP3A4 
low-frequency variants had similar median cumulative doses to first instance of grade 2 or higher 
PN and a similar proportion of PN events compared to non-carriers (Figure 3.5). For PRX, a total 
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of 8 intronic rare variants (rs117182727, rs117780513, rs117952516, rs142805539, 
rs145046254, rs1981957, rs3947852, rs78458775) were analyzed in the gene-based association 
test (Figure 3.6). Patients with at least one rare genetic variant in PRX have higher incidence of 
reported grade 2 or higher PN events than those without PRX variants.  
 
 
Figure 3.5 Cumulative dose to first instance of grade 2 or higher PN event in each treatment arm 
for those with and without low-frequency noncoding variants in CYP3A4 (left). The median 
cumulative doses to first instance of grade 2 or higher PN event and number of patients with and 
without a reported grade 2 or higher PN event in each category are displayed below the boxplots. 
Annotation of low-frequency variant types aggregated in CYP3A4 from the candidate gene-based 
analysis is shown in the inset (right).  
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Figure 3.6 Cumulative dose to first instance of grade 2 or higher PN event in each treatment arm 
for those with and without rare variants in PRX (left). The median cumulative doses to first 
instance of grade 2 or higher PN event and number of patients with and without a reported grade 
2 or higher PN event in each category are displayed below the boxplots. Annotation of low-
frequency variant types aggregated in PRX from the candidate gene-based analysis is shown in 
the inset (right).  
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DISCUSSION 
 
In these discovery genome-wide analyses, we identified several genes with rare and low-
frequency variation that may contribute to the risk of grade 2 or higher peripheral neuropathy, 
albeit no gene-based associations achieved unadjusted P value thresholds. Among the genes with 
lowest association P value, four genes (PRDM16, SHC4, PEAR1 and TRIOBP) were further 
prioritized based on expression levels in human DRG and/or previously described biologically-
relevant functional activity in neurons.  
In the exome-wide discovery analysis, the most significant gene association with grade 2 
or higher MTA-induced peripheral neuropathy was PRDM16, a gene that encodes for zinc finger 
transcriptional coregulator PRDM16 and is mostly known for its activity in development of 
brown adipose tissue15  However, a recent study investigated its role in regulating epigenetic 
state of transcriptional enhancers for neurogenesis and neuronal migration in cortical neurons16. 
Interestingly, the missense exonic variant rs371654192 identified in PRDM16 may disrupt 
binding of early growth response-1 (EGR-1), an overall marker for neuronal activity and an 
important nerve growth factor (NGF)-stimulated transcription factor that mediates inflammatory 
responses to tissue damage17. Since its activity could be related to neuronal response to 
chemotherapy exposure, imbalance in PRDM16 activity may impair nerve repair mechanisms 
needed to combat chemotherapy-induced damage and thus increase patient susceptibility to 
MTA-induced peripheral neuropathy. 
From the low-frequency variant analysis, we further prioritized SHC4, which encodes for 
a member of the Shc family of adaptor proteins that functions as a platform to recruit and 
transduce extracellular signaling events primarily through MAPK and PI3K activation18. 
Alongside many CIPN studies that focused on the inflammatory response due to increased PI3K 
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signaling19, there is also evidence that nerve growth factor (NGF)-mediated phosphorylation of 
Shc proteins can signal its translocation to the cytoskeleton and directly bind F-actin in 
neurons20. NGF-mediated Shc activity was also shown to initiate RhoA activation via Ras and 
initiate cytoskeletal organization21,22.  Although the functional role of Shc proteins in sensory 
neurons are still unknown, it is plausible to suggest that improper Shc function may lead to the 
inability to signal appropriate inflammatory signals and cytoskeletal rearrangements after nerve 
injury.   
The gene PEAR1 (platelet endothelial aggregation receptor 1) encodes for a protein that 
is primarily known for its role in platelet activation23. However, recent studies in peripheral 
nerves implicated its function in satellite glia of DRG24 and showed mutations in PEAR1 cause 
increased sensory excitability via crosstalk between sensory neurons and non-neuronal 
supporting cells25. This notion is in accordance with the observed increased incidence in grade 2 
or higher PN in patients who carry deleterious variation in PEAR1. The SNP rs41299597 
observed in PEAR1 is also an eQTL for SLC25A44, a member of solute carrier transporters 
within the inner mitochondrial membrane26, in tibial nerve tissue, supporting the idea that 
mitochondrial function contributes to altered excitability of peripheral neurons27. Furthermore, it 
is notable that one exonic SNP (rs147639000) identified in PEAR1 is linked to intronic variants 
of ARHGEF11, a member of guanine nucleotide exchange factors (GEFs) for RhoA GTPase. 
Beutler et al. 4 previously associated common variation in CMT genes ARHGEF10 and PRX 
with susceptibility of chemotherapy-induced neuropathy. Intriguingly, patients harboring 
variation in ARHGEF10 were more likely to experience peripheral neuropathy symptoms 
induced by chemotherapy. This connection between variation in congenital neuropathy genes 
	 143	
and susceptibility to drug-induced neuropathies has also been highlighted in other genome-wide 
association studies8,28. 
TRIOBP encodes for a protein that functions primarily to control neural development and 
actin cytoskeleton organization via stabilization of F-actin structures. Mutations in exons 6-9 are 
associated with inherited sensorineural hearing impairment29. While the bioinformatic analysis 
on TRIOBP low-frequency variants predicted disruption in binding of transcription factors (i.e., 
EGR-1 and GR) essential to promote neuronal growth, we observed a potential protective effect 
against occurrence of developing grade 2 or higher peripheral neuropathy in those with TRIOBP 
low-frequency variants within CALGB 40502. All the “deleterious” mutations observed lie 
within exon 7, suggesting some functional consequence to TRIOBP. Nonetheless, considering 
little is understood about the role of TRIOBP in sensory nociceptive peripheral neurons 
additional mechanistic investigation is warranted to clarify its role.  
None of the 242 candidate genes in the exome-wide discovery analysis using only 
“deleterious” coding variants met the criteria for further investigation. The lowest P value for 
gene association was observed for CACNB 2 (P = 3.95E-03) encoding for a voltage-dependent 
calcium channel with low human DRG expression (FPKRM = 1.32) and thus, was not further 
explored. To explore the role of noncoding regulatory variation in these candidate genes, we 
performed a candidate gene-based analysis using solely noncoding variants. The most significant 
association was observed with Actin Gamma 1 or ACTG1, which was also highly expressed in 
DRGs. By virtue of the candidate-gene selection (Table 3.1), common variant rs1135989 in 
ACTG1 has previously been implicated in increased risk to vincristine-induced peripheral 
neuropathy9,30. It will be important to examine genetic variation in ACTG1 in larger populations 
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of patients treated with both microtubule stabilizing and destabilizing drugs to resolve its role in 
risk of PN. 
It should be noted that our candidate gene study also features CYP3A4 and PRX among 
the genes with most significant association, which have been previously implicated in other 
whole exome sequencing CIPN studies. PRX, encodes for periaxin protein that is responsible for 
maintenance of peripheral nerve myelin with roles in remyelination after nerve injury. Mutations 
in PRX are causal to CMT neuropathy type 4F and are characterized by significant demyelination 
of peripheral nerves as a result of impaired myelin peripheral sheaths31. Following the same 
direction of effect observed in a previous study4, low-frequency SNPs in the noncoding regions 
of PRX are associated with increasing rate of PN in CALGB 40502 and less tolerance to 
cumulative MTA exposure. This further emphasizes the notion that CMT mutation carriers are 
predisposed to development of peripheral neuropathy when exposed to microtubule-targeting 
agent chemotherapy. Noncoding variation in CYP3A4 was not associated with increased risk of 
MTA-induced PN events, in contrast to coding variants reported by others6. It is plausible that 
noncoding variation does not reduce the drug metabolizing activity enough to increase the 
overall drug exposure, although this should be examined in larger populations. Future work will 
be focused on exploring these genetic effects in risk of developing MTA dose modifications, 
which may be a more reflective and sensitive to genetic variation in the genes identified above to 
CIPN.  
Although more functional sensory neuron studies and genetic validation studies in 
independent cohorts are needed to corroborate the contributions of these genes to MTA-induced 
PN, these discovery analyses highlight the importance of Rho GTPase signaling in drug-induced 
peripheral neuropathies. A number of genome-wide association studies have identified other 
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genes (FGD4, EPHA4/5/6/8, ARHGEF10, S1PR1, SEPT5)32 that have converged on the Rho 
GTPase signaling pathway, suggesting that susceptibility to CIPN may be related to 
dysregulation in actin cytoskeleton reorganization. It remains unclear whether dysregulation is 
directly triggered by MTA accumulation within the sensory neurons or during the critical process 
to reinnervate the epidermis and restore sensory function after chemotherapy-induced nerve 
damage.  
While our study discovered some relevant genes, this study has several caveats. As the 
majority of pharmacogenetic studies, these findings are limited by low study sample size and 
further restricted by stratification of each treatment arm. As a result, the study is largely 
underpowered to identify significant associations with direct clinical utility. However, our study 
still discovered some biologically-relevant genes among those with the lowest P value for 
association that support previous mechanistic investigations into how chemotherapy-induced 
neuropathy develops. Future work will include a closer examination of rare and low-frequency 
variants among extreme phenotypes (i.e., those treated with large amount of MTA doses without 
any reported neuropathy events compared to those with immediate PN events after low MTA 
doses). An extreme responder-like analysis might reveal important variation that may be directly 
actionable and provide interesting additional mechanistic insights critical in toxicity progression.  
While our additional custom capture focused on identifying novel variants in genes with 
known biological function in axon guidance, MTA pharmacokinetics, and peripheral 
neuropathies, an important limitation in our study is the inability to capture flanking regions, 
which are more likely to contribute to regulatory activity of genes33. To address this, future work 
will include the imputation of these genomic regions using the sequencing information, which 
might highlight candidate genes that were not identified in the analyses presented here. 
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Another limitation in the analyses is that MTA-induced PN was defined using the NCI-
CTCAE grading scale, which may not completely encompass the progression of neuropathy 
symptoms34–36. Future work will also investigate the use of patient-reported outcomes to yield a 
phenotype that embodies a more comprehensive perspective on neuropathy progression, which 
may reveal additional genes associated with development of drug-induced neuropathy. In fact, an 
earlier whole exome sequencing study utilized patient-reported outcomes to define severe 
peripheral neuropathy cases, which revealed the fruitful associations of CMT mutations with risk 
of developing CIPN4.  
Lastly, another important next step is to explore these gene regions in independent 
cohorts and perform functional validation. Due to the limited number of sequencing studies 
investigating CIPN, it may be necessary to attempt genetic validation in cohorts with genome-
wide imputed data (e.g. CALGB 40101 from Chapter 2). Although genetic imputation cannot 
infer genotype calls for rare variants, there may be some sensitivity in exploring low-frequency 
variation in these genomic regions to validate our findings. Mechanistic validation of any 
genomic findings will also be essential in future work. The use of human sensory neurons 
derived from induced pluripotent stem cells would also be a crucial next step to further implicate 
the relevance of these identified genes to sensitize or mitigate chemotherapy-stimulated sensory 
neuronal damage. 
Overall, our study highlighted novel genes involved in Rho GTPase signaling that may 
influence the mechanisms underlying sensory neuropathy caused by MTA therapy. As more 
genes are discovered from human genetic and functional genomic studies focused on CIPN, we 
will further uncover the exact molecular mechanisms that drive the development of this complex 
toxicity and reveal a clearer understanding of how the neuropathic symptoms manifest. 
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CHAPTER 4:  Predicting Dose-Limiting Chemotherapy-Induced Peripheral Neuropathy 
Using Early Patient-Reported Outcomes and Genome-Wide Data from Breast Cancer 
Patients in CALGB 40502 
 
INTRODUCTION 
Chemotherapy-induced neuropathy is one of the main adverse events that contribute to dose 
reductions and therapy discontinuation, potentially diminishing overall chemotherapy benefit1. In 
addition, cancer survivors who experience severe chemotherapy-induced sensory peripheral 
neuropathy (CIPN) suffer from long-term neurological effects that hinder daily functions2,3. Due 
to these complications, there is an increasing need to appropriately monitor and manage CIPN 
symptoms during chemotherapy to minimize lasting impairments to health-related quality of life. 
Although CIPN is frequently described as tingling/numbness or abnormal sensations that 
initiate at the fingertips and toes, it is still challenging to quantifiably capture the onset and 
severity of this neurotoxicity, in part due to interindividual differences in patient experience. 
Common approaches to survey CIPN symptoms include clinician-based assessments (e.g., NCI-
CTCAE), patient-reported outcomes (e.g., CIPN20, EORTC, FACT/GOG-Ntx), and objective 
diagnostic tests (e.g., nerve conduction studies)4,5. While a combination of these approaches is 
likely most suitable to fully describe CIPN symptoms, clinician-based criteria and patient-
reported questionnaires are the most commonly used in clinical trials and clinical practice4,6. 
Previous studies comparing these two types of assessments have shown that clinician-
based criteria tend to underreport the severity of sensory neuropathy symptoms7 and miss early 
signs of neurological impairment8–10. Because of these findings, there has been increasing 
recognition of patient-reported outcomes as a means to collect a more comprehensive view of 
CIPN progression over the course of treatment and/or to prospectively monitor, evaluate, and 
manage CIPN symptoms. Human genetic association studies have even started to use patient-
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reported data to discover novel genetic markers that may help identify at-risk patients6,11. 
However, there is still a gap in understanding how to implement patient-reported outcomes and 
genetics as tools to predict risk for dose-limiting neuropathy events.  
In this study, we investigated whether early patient-reported outcomes and genome-wide 
data can be used to predict dose reductions, dose delays, or therapy discontinuations (RDD) due 
to sensory peripheral neuropathy. Our study is motivated by the need to develop an effective and 
simple strategy for prevention of dose-limiting neuropathy events, which requires early 
prediction of patient susceptibility to developing severe neuropathy. Validation of the findings 
presented here will provide the first step to achieving this clinical application and lead to future 
studies of the proactive utilization of large-scale patient-reported outcomes to monitor and 
control CIPN. 
 
MATERIALS AND METHODS 
Participants 
All study participants were enrolled in Cancer and Leukemia Group B (CALGB) 40502, a 
randomized three-arm phase III trial conducted to determine whether nanoparticle albumin-
bound (nab) paclitaxel or ixabepilone is superior to paclitaxel as first-line therapy for patients 
with advanced breast cancer. CALGB 40502 was open from October 2008 through November 
2011, enrolling a total of 799 subjects. Eligibility criteria for enrollment has been previously 
described12. All patients provided written informed consent for both the treatment and 
pharmacogenomic protocols that met state, federal, and institutional guidelines. Patient 
characteristics for the entire clinical trial cohort were previously described12,13 (Chapter 2, 
Results). 
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Curation of FACT-GOG/Ntx scores  
Patient-reported neurotoxicity assessment in CALGB 40502 was performed using the 
FACT/GOG-Ntx subscale (C-669 v5). The FACT/GOG-Ntx subscale is a validated 11-item 
questionnaire that uses a 5-pt Likert-like scale (“Not at all”; “A little bit”; “Somewhat”; “Quite a 
bit”; “Very much”) to evaluate symptoms associated with chemotherapy-induced neuropathy. 
Patients were asked to answer the questionnaire every treatment cycle, considering their 
experiences and symptoms for the last week. From the entire subscale, four items capturing 
experiences of sensory peripheral neuropathy and two items focusing on dysfunctional 
neuropathy (Table 4.1) were considered, and each item response was converted to scores 0-4. 
For each assessment, the four sensory neuropathy scores (fgsum4) and all six scores (fgsum6) 
were summed to quantitate the cumulative peripheral neuropathy symptoms experienced. A total 
of 6,207 FACT/GOG-Ntx assessments across the 799 randomized patients were curated. 
Assessments were matched with treatment cycle times using FACT/GOG-Ntx assessment week 
period, where a match was only implemented if the assessment week period lies within four days 
of a treatment cycle start and end dates (Figure 4.1). Baseline assessment entries were 
subsequently included for those patients with available matched data. After this process, a total 
of 5,998 FACT/GOG-Ntx assessments across 719 patients (PRO cohort) were used for further 
analysis.  
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Table 4.1 FACT/GOG-Ntx questionnaire items capturing experiences of chemotherapy-induced 
neuropathy. 
 FACT/GOG-Ntx subscale items Summed scores 
Sensory 
neuropathy 
I have numbness and tingling in my hands. 
fgsum4 
fgsum6 
I have numbness and tingling in my feet. 
I feel discomfort in my hands. 
I feel discomfort in my feet. 
Dysfunctional 
neuropathy 
I have trouble buttoning buttons.  
I have trouble feeling the shape of small 
objects when they are in my hand. 
 
 
Figure 4.1 Schematic workflow of FACT/GOG-Ntx score curation and definition of PRO 
cohort. 
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Identifying an early predictor for sensory neuropathy 
To investigate if patient-reported outcomes data can be used as a predictive marker for 
neuropathy, we considered six different constructs of fgsum4 and fgsum6 scores: fgsum4 or 
fgsum6 score at treatment cycle 3 (fgsum4t=3, fgsum6t=3), slope of fgsum4 or fgsum6 scores until 
treatment cycle 3 (slopefgsum4,t=0-3, slopefgsum6,t=0-3), and area under the curve (AUC) of fgsum4 or 
fgsum6 scores until treatment cycle 3 (AUCfgsum4,t=0-3, AUCfgsum6,t=0-3). Each construct was tested 
as a predictor in a logistic regression for severe neuropathy events in the PRO cohort (n = 719), 
where each model was trained on 75% of data and a model AUCROC was calculated on the 
remaining 25% of the data to determine the best early predictor of sensory neuropathy. Severe 
neuropathy events were defined by dose reductions or delays and therapy discontinuations 
specifically denoted for sensory peripheral neuropathy. The construct with the largest model 
AUCROC was chosen for further prediction analyses. For the fgsum4t=3 and fgsum6t=3, the closest 
fgsum4 or fgsum6 score to treatment cycle 3 is used for those who do not have scores at cycle 3 
(n=159), where a mean score is used when the closest scores are equidistant in time or two scores 
are captured for a given treatment cycle time. Patients with scores more than two cycles away 
from cycle 3 were excluded (n = 3). Patients who experienced RDD for sensory peripheral 
neuropathy before cycle 3 were also excluded, leaving 703 fgsum4t=3 and fgsum6t=3 
measurements. For slope predictors, only those with at least three scores through cycle 3 were 
included (n=629), and slopes were calculated using a linear regression with fgsum4 or fgsum6 
scores and treatment cycle time. For AUCfgsum4,t=0-3 or AUCfgsum4,t=0-3, all scores until cycle 3, 
regardless of the number of scores, were used to calculate score AUCs using the trapezoid rule. 
No patients were excluded, leaving 719 AUCfgsum4,t=0-3 and AUCfgsum6,t=0-3 measurements.  
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Genotype Data 
A similar quality control workflow was used to isolate genotype data and has been described in a 
previous chapter (Chapter 2, Methods). Briefly, from those enrolled in CALGB 40502, a total of 
633 consented patients with DNA samples were genotyped using the Illumina 
HumanOmniExpressExome-8 BeadChip, interrogating 964,055 SNPs with coverage of common 
variants and additional exonic content. Genotyping data were filtered using a standard quality 
control (QC) pipeline. All samples were filtered for low call rate (< 0.99) or low genotyping 
performance; none were excluded. Identity-by-descent (IBD) analysis identified the presence of 
two closely related individuals, which were excluded and found later to be a plating error. An X 
chromosome heterozygosity estimation identified three genetic males that were removed, leaving 
628 subjects for further analysis. Principal component analysis (PCA) was performed using 
directly genotyped single nucleotide polymorphisms (SNPs) of all 628 study subjects to 
determine genetic ancestry with the GenABEL R package. A total of 478 subjects of European 
genetic ancestry were identified by using the mean values for the first 3 PC vectors with self-
declaring “White” race and “Non-Hispanic” / “Unknown” ethnicity. SNPs were excluded using 
the following quality control filters: minor allele frequency (MAF) < 0.05, deviation from 
Hardy-Weinberg equilibrium with P value < 1E-08, call rate < 0.99, and non-autosomal SNPs, 
leaving 593,989 SNPs for genome-wide analysis. Among the 478 genetically estimated 
Europeans with genotyped data, a total of 382 patients with FACT/GOG-Ntx information (PRO 
EUR cohort) was used in the prediction analysis. From the remaining 150 study subjects of non-
European genetic ancestry, a total of 120 with FACT/GOG-Ntx information were used as the 
validation set (PRO non-EUR cohort). 
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Statistical analysis for comparisons between patient-reported and clinician-based assessments 
All comparisons of fgsum4 and fgsum6 scores between those who experience grade 2 or higher 
neuropathy events (defined by NCI NCI-CTCAE v3.0) and those who had no reported 
neuropathy events were evaluated using the Mann-Whitney-Wilcoxon test. Differences in all 
constructs of fgsum4 and fgsum6 scores between those who experience RDD and those who had 
no reported RDD events for sensory peripheral neuropathy were also similarly tested using the 
Mann-Whitney-Wilcoxon test. All tests were conducted using the function wilcox.test under the 
R v3.5.3 statistical environment.  
 
Prediction analysis 
The final prediction model was determined using the PRO EUR cohort with dose reductions or 
delays and therapy discontinuations (RDD) specific for sensory peripheral neuropathy as the 
primary outcome. To identify any clinical covariates, a stepwise backward selection of clinical 
characteristics on the PRO cohort, including self-reported race/ethnicity, age, hormone receptor 
status, bevacizumab therapy, visceral metastases, diabetic status, prior taxane status, and body 
surface area, was performed using a conditional logistic regression stratifying for treatment arm; 
no clinical features remained. After identifying the best early predictor for sensory neuropathy, a 
final PRO prediction model for RDD was generated on PRO EUR cohort (n = 382) using 
slopefgsum6,t=0-3 as the primary predictor within the framework of a conditional logistic regression, 
stratifying for treatment arm. The final PRO model was validated on the PRO non-EUR cohort 
(n = 120). 
To investigate whether genome-wide association data would improve the final PRO 
prediction model, a 10-fold cross-validation was performed to generate a prediction model with 
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slopefgsum6,t=0-3 and genetics using the PRO EUR cohort (Figure 4.2). First, samples were 
subdivided into 10 groups of approximately equal sizes, where one group was reserved as the test 
set and each individual was only used once in a single test set. GWAS was performed on each 
training set to identify SNPs associated with RDD status (P value threshold < 1E-04). To 
generate ten initial models, a stepwise backwards regression was performed with slopefgsum6,t=0-3 
and the identified SNPs using a conditional logistic regression, stratifying for treatment arm, on 
each training set. The final PRO genetic model included slopefgsum6,t=0-3 and SNPs that remained 
in at least 50% of the initial models, and a model AUCROC was calculated on the PRO non-EUR 
cohort. This analysis was conducted under the R v3.5.3 statistical environment14. 
 
Figure 4.2 Overview of the PRO genetic prediction model. A 10-fold cross-validation in PRO 
EUR (n = 382) cohort was performed to build a prediction model using slopefgsum6,t=0-3 with 
SNPs. Ten GWAS were performed to identify SNPs associated with RDD specific for 
neuropathy. A stepwise backwards regression with SNPs with association of P < 1E-04 was 
performed to build ten initial PRO genetic models. A final PRO genetic prediction model was 
created using slopefgsum6,t=0-3 and SNPs that remained in at least 50% of the ten initial models, 
and a model AUCROC was generated using the PRO non-EUR cohort. 
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RESULTS 
Among the 799 patients randomized in CALGB 40502, a total of 6,207 FACT/GOG-Ntx 
assessment entries were collected during the clinical trial and were used as patient-reported 
outcomes of sensory peripheral neuropathy. Assessments were matched with treatment cycle and 
dosing information using completion dates with treatment cycle start and end dates. Patients with 
no recorded FACT/GOG-Ntx and treatment cycle data (n = 17), patients with either no recorded 
treatment cycle data (n = 6) or FACT/GOG-Ntx data (n = 14), patients with no matching 
FACT/GOG-Ntx entries (n = 9), and patients with only baseline FACT/GOG-Ntx entries (n = 
34) were excluded. After this matching process, a total of 5,998 FACT/GOG-Ntx assessments 
across 719 patients (PRO cohort) were used for further analysis, where 75% of patients have one 
to 10 assessments and the median number of assessments per patient is six (Figure 4.3). We 
focused on characterizing the sum of the four sensory peripheral neuropathy items (fgsum4) and 
sum of these four items in addition to two dysfunctional neuropathy items (fgsum6) as the 
primary patient-reported measurements for chemotherapy-induced neuropathy. (Table 4.1). 
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Figure 4.3 Distribution of FACT/GOG-Ntx assessments captured for patients in CALGB 40502. 
The numbers at the top of each bar represents the number of patients with x amount of 
FACT/GOG-Ntx assessments. The median number of FACT/GOG-Ntx assessments per patient 
is six. 
 
Patient-reported scores capture neuropathy events in CALGB 40502 
Before assessing whether patient-reported outcomes can be used as an early predictor of 
significant neuropathy, we assessed whether fgsum4 and fgsum6 scores capture clinician-
reported sensory peripheral neuropathy events. In CALGB 40502, neurotoxicity adverse events 
were assessed using the NCI-CTCAE grading scale, where any significant grade 2 or higher 
peripheral neuropathy events were required to be reported. Patients with reported grade 2 or 
higher peripheral neuropathy events generally had higher fgsum4 and fgsum6 scores compared 
to those without any reported events, regardless of treatment arm (Figure 4.4). The score 
differences between these two groups are observed as early as treatment cycle 1 in the paclitaxel 
(Pfgsum4 = 7.92E-04, Pfgsum6 = 1.76E-03, Mann-Whitney-Wilcoxon test) and nab-paclitaxel 
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(Pfgsum4 = 0.048; Pfgsum6 = 0.059; Mann-Whitney-Wilcoxon test) arms and treatment cycle 2 in the 
ixabepilone arm (Pfgsum4 = 1.64E-05; Pfgsum6 = 4.25E-05; Mann-Whitney-Wilcoxon test) (Figure 
4.4). On an individual level, fgsum4 and fgsum6 scores captured the time at which peripheral 
neuropathy events occur (Figure 4.5). Furthermore, to determine if the summed scores are 
sensitive in distinguishing patients with and without neuropathy, fgsum4 and fgsum6 scores at 
time of reported NCI-CTCAE grade 2 or higher neuropathy event were compared with those at 
time of last assessment for patients without any reported neuropathy events. All item scores and 
the cumulative fgsum4 and fgsum6 scores are statistically different between patients with and 
without grade 2 or higher neuropathy (Figure 4.6; P < 2E-16, Mann-Whitney-Wilcoxon test). 
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Figure 4.4 Box plots of fgsum4 and fgsum6 scores at baseline and for the first ten treatment 
cycles. Score distributions are binned by those with reported NCI-CTCAE grade 2 or higher 
neuropathy events (blue) and those with no reported neuropathy events (pink).  Each panel 
represents the three treatment arms in CALGB 40502. Score differences between two patient 
groups are statistically significant as early as cycle 1 for paclitaxel (Pfgsum4 = 7.92E-04, Pfgsum6 = 
1.76E-03) and nab-paclitaxel (Pfgsum4 = 0.048; Pfgsum6 = 0.059), and treatment cycle 2 in the 
ixabepilone arm (Pfgsum4 = 1.64E-05; Pfgsum6 = 4.25E-05). Differences in scores at each cycle are 
tested using the Mann-Whitney-Wilcoxon test. 
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Figure 4.5 Heatmap of scores for two example patients, one without any reported peripheral 
neuropathy events (A) and one with a reported NCI-CTCAE grade 2 or higher peripheral 
neuropathy event at treatment cycle 4 (B). Each box represents a score for each sensory 
neuropathy item (rows) at each treatment cycle time point captured (columns). A response of 
“not at all” corresponds to a score of 0 while a response of “very much” corresponds to a score 
of 4. 
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Figure 4.6 Heatmaps of sensory neuropathy items, fgsum4 and fgsum6 for all patients. Each box 
in each panel represents a score for each sensory neuropathy item and fgsum4 and fgsum6 (rows) 
for each individual (columns). A response of “not at all” corresponds to a score of 0 while a 
response of “very much” corresponds to a score of 4. Scores displayed for patients with no 
reported neuropathy (left panel, n = 348) were taken at the last assessment. Scores displayed for 
those with neuropathy (right panel, n = 326) were taken at the time of reported NCI-CTCAE 
grade 2 or higher neuropathy event. Each item score or summed score was statistically 
significant between patients with no reported neuropathy and those with grade 2 or higher 
neuropathy (P < 2E-16, Mann-Whitney-Wilcoxon test). 
 
In the clinical trial setting, peripheral neuropathy adverse events are often reported using 
the NCI-CTCAE grading scale; however, in standard clinical practice, these events are often 
reported as dose reductions and delays due to peripheral neuropathy or as the reason for therapy 
discontinuation. In CALGB 40502, the median cycle time to first dose reduction/delay or therapy 
discontinuation for peripheral neuropathy is cycle six, five, and five in the paclitaxel, nab-
paclitaxel, and ixabepilone arms, respectively (Figure 4.7). Patients with reported dose 
reductions/delays or therapy discontinuations for peripheral neuropathy generally had higher 
fgsum4 and fgsum6 scores compared to those without any reported events as early as treatment 
cycle 2, regardless of treatment arm (Figure 4.8; paclitaxel, Pfgsum4 = 0.0277, Pfgsum6 = 0.0205; 
nab-paclitaxel, Pfgsum4 = 4.74E-03, Pfgsum6 = 4.09E-03; ixabepilone, Pfgsum4 = 1.91E-05, Pfgsum6 = 
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7.13E-05; Mann-Whitney-Wilcoxon test). Similar to sensitivity in distinguishing patients with 
grade 2 or higher peripheral neuropathy, fgsum4 and fgsum6 scores at time of first dose 
reduction/delay or therapy discontinuation for peripheral neuropathy were significantly different 
to those at time of last assessment for the remaining patients (Figure 4.9; Pfgsum4, Pfgsum6 < 2.2E-
16, Mann-Whitney-Wilcoxon test). Overall, both fgsum4 and fgsum6 scores can distinguish 
between those who experience peripheral neuropathy (e.g. grade 2 or higher neuropathy and dose 
reductions/delays or therapy discontinuation) and those who did not, regardless of treatment arm. 
Because dose reductions/delays or therapy discontinuations are significant dose-limiting events 
that may reduce overall chemotherapy benefit, they were defined as our main phenotype for 
predicting sensory neuropathy using either fgsum4 or fgsum6 scores in subsequent analyses.  
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Figure 4.7 Time of dose reductions/delays or therapy discontinuation for sensory neuropathy 
observed in each treatment arm of CALGB 40502. The numbers above the bars represent the 
number of patients with the first dose reduction/delay or therapy discontinuation at the given 
treatment cycle time. Median treatment cycle time to first dose reduction/delay or therapy 
discontinuation for sensory neuropathy for each treatment arm is shown as the vertical red 
dashed line. Total number of patients with dose reductions/delays or therapy discontinuation for 
sensory neuropathy is 72, 80, and 69 in the paclitaxel, nab-paclitaxel, and ixabepilone arms, 
respectively. 
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Figure 4.8 Box plots of fgsum4 and fgsum6 scores at baseline and for the first ten treatment 
cycles. Score distributions are binned by those with reported dose reductions/delays or therapy 
discontinuation for neuropathy (blue) and those without reported events (pink).  Each panel 
represents one of the three treatment arms in CALGB 40502. Score differences between the two 
patient groups are statistically significant as early as cycle 2 for all treatment arms (paclitaxel, 
Pfgsum4 = 0.0277, Pfgsum6 = 0.0205; nab-paclitaxel, Pfgsum4 = 4.74E-03, Pfgsum6 = 4.09E-03; 
ixabepilone, Pfgsum4 = 1.91E-05, Pfgsum6 = 7.13E-05). Differences in scores at each cycle are tested 
using the Mann-Whitney-Wilcoxon test. 
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Figure 4.9 Heatmaps of fgsum4 and fgsum6 scores at time of first dose reduction/delay or 
therapy discontinuation. Each box in each panel represents the fgsum4 and fgsum6 score for 
each patient. Scores displayed for patients with no reported dose reduction/delay or 
discontinuation (RDD) (left panel, n = 504) were taken at the last assessment. Scores displayed 
for those with reported dose reduction/delay or discontinuation (right panel, n = 212) were taken 
at the time of reported event. Patients with fgsum4/fgsum6 scores that could not be captured 
within two cycles of reported RRD or last assessment time were excluded from the plot (n = 3). 
Differences in all scores between patients with no reported neuropathy and those with dose 
reductions/delays or therapy discontinuation for peripheral neuropathy are significant 
(Pfgsum6,Pfgsum4 < 2.2E-16, Mann-Whitney-Wilcoxon test). 
 
 
Characteristics of early predictors for RDD using patient-reported outcomes 
To investigate if patient-reported outcomes data can be used as an early predictive marker for 
neuropathy, we considered six different constructs of fgsum4 and fgsum6 scores: fgsum4 or 
fgsum6 score at treatment cycle 3 (fgsum4t=3, fgsum6t=3), slope of fgsum4 or fgsum6 scores until 
treatment cycle 3 (slopefgsum4,t=0-3, slopefgsum6,t=0-3), and area under the curve of fgsum4 or fgsum6 
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scores until treatment cycle 3 (AUCfgsum4,t=0-3, AUCfgsum6,t=0-3). Treatment cycle 3 was chosen as 
the last considered time point since most dose reductions/delays or therapy discontinuations for 
peripheral neuropathy occur around treatment cycle 5 (Figure 4.7). Figure 10 shows the 
distribution of the AUCfgsum4,t=0-3 measurements in each treatment arm, where the median 
AUCfgsum4,t=0-3 values were 4, 6, and 3 for paclitaxel, nab-paclitaxel, and ixabepilone, 
respectively. Differences in AUCfgsum4,t=0-3 between patients with reported dose reductions/delays 
or therapy discontinuations for peripheral neuropathy are significant in all three treatment arms 
(Figure 4.10). A similar distribution of AUCfgsum6,t=0-3 measurements is shown in Figure 4.11, 
where the median AUCfgsum6,t=0-3 values were 4.5, 6.5, and 3 for paclitaxel, nab-paclitaxel, and 
ixabepilone, respectively. Similarly to AUCfgsum4,t=0-3, patients with RDD had significantly higher 
AUCfgsum6,t=0-3 than those without RDD for peripheral neuropathy (Figure 4.11). 
For scores at cycle 3, the median fgsum4t=3 scores were 2, 4, and 2 while the median 
fgsum6t=3 scores were 3, 5, and 2 for paclitaxel, nab-paclitaxel, and ixabepilone, respectively 
(Figures 4.12-4.13). Patients with reported dose reductions/delays or therapy discontinuations for 
peripheral neuropathy scored higher than those without these events in all three treatment arms 
(Figures 4.12-4.13). Similar to fgsum4t=3 scores, fgsum6t=3 scores are also higher in patients with 
RDD than those who do not experience RDD for sensory peripheral neuropathy (Figure 4.13). 
Figures 4.14-4.15 show the distribution of the slopefgsum4,t=0-3 and slopefgsum6,t=0-3 
measurements in each treatment arm. The mean slopefgsum4,t=0-3 values were 0.889, 1.320, and 
0.969  while the mean slopefgsum6,t=0-3 values were 1.04, 1.60, and 1.15 for paclitaxel, nab-
paclitaxel, and ixabepilone, respectively. Slopes using both fgsum4 and fgsum6 calculated from 
patients with reported dose reductions/delays or therapy discontinuations for peripheral 
neuropathy are significantly higher than those without RDD (Figures 4.14-4.15). 
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Figure 4.10 Distribution of AUCfgsum4,t=0-3 and relationship to dose reductions/delays or therapy 
discontinuation. (A) Distribution of AUCfgsum4,t=0-3 measurements observed in each treatment arm 
of CALGB 40502, where the numbers above the bars represent the number of patients with a 
given AUCfgsum4,t=0-3 measurement. Median AUCfgsum4,t=0-3 measurements are shown as red dotted 
vertical lines. (B) Comparison of AUCfgsum4,t=0-3 measurements between those who experience 
dose reduction/delay or discontinuation for sensory peripheral neuropathy (blue) and those who 
do not have any reported events (pink). The number of measurements in each boxplot are 
denoted on the x-axis. Differences between the two groups are significant in all three treatment 
arms and P values are shown in below plot (Mann-Whitney-Wilcoxon test). 
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Figure 4.11 Distribution of AUCfgsum6,t=0-3 and relationship to dose reductions/delays or therapy 
discontinuation. (A) Distribution of AUCfgsum6,t=0-3 measurements observed in each treatment arm 
of CALGB 40502, where the numbers above the bars represent the number of patients with a 
given AUCfgsum6,t=0-3 measurement. Median AUCfgsum6,t=0-3 measurements are shown as red dotted 
vertical lines. (B) Comparison of AUCfgsum6,t=0-3 measurements between those who experience 
dose reduction/delay or discontinuation for sensory peripheral neuropathy (blue) and those who 
do not have any reported events (pink). The number of measurements in each boxplot are 
denoted on the x-axis. Differences between the two groups are significant in all three treatment 
arms and P values are shown in below plot (Mann-Whitney-Wilcoxon test). 
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Figure 4.12 Distribution of fgsum4t=3 and relationship to dose reductions/delays and therapy 
discontinuation. (A) Distribution of fgsum4t=3 measurements observed in each treatment arm of 
CALGB 40502, where the numbers above the bars represent the number of patients with a given 
fgsum4t=3 measurement. Median fgsum4t=3 measurements are shown as red dotted vertical lines. 
(B) Comparison of fgsum4t=3 measurements between those who experience dose reduction/delay 
or discontinuation for sensory peripheral neuropathy (blue) and those who do not have any 
reported events (pink). The number of measurements in each boxplot are denoted on the x-axis. 
Differences between the two groups are significant in all three treatment arms and P values are 
shown in below plot (Mann-Whitney-Wilcoxon test). 
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Figure 4.13 Distribution of fgsum6t=3 and relationship with dose reductions/delays or therapy 
discontinuation. (A) Distribution of fgsum6t=3 measurements observed in each treatment arm of 
CALGB 40502, where the numbers above the bars represent the number of patients with a given 
fgsum6t=3 measurement. Median fgsum6t=3 measurements are shown as red dotted vertical lines.  
(B) Comparison of fgsum6t=3 measurements between those who experience dose reduction/delay 
or discontinuation for sensory peripheral neuropathy (blue) and those who do not have any 
reported events (pink). The number of measurements in each boxplot are denoted on the x-axis. 
Differences between the two groups are significant in all three treatment arms and P values are 
shown in below plot (Mann-Whitney-Wilcoxon test). 
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Figure 4.14 Distribution of slopefgsum4,t=0-3 and relationship to dose reductions/delays and therapy 
discontinuation. (A) Distribution of slopefgsum4,t=0-3 measurements observed in each treatment arm 
of CALGB 40502, where the numbers above the bars represent the number of patients with a 
given slopefgsum4,t=0-3 measurement. Median slopefgsum4,t=0-3 measurements are shown as red 
dotted vertical lines.  (B) Comparison of slopefgsum4,t=0-3 measurements between those who 
experience dose reduction/delay or discontinuation for sensory peripheral neuropathy (blue) and 
those who do not have any reported events (pink). The number of measurements in each boxplot 
are denoted on the x-axis. Differences between the two groups are significant in all three 
treatment arms and P values are shown in below plot (Mann-Whitney-Wilcoxon test). 
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Figure 4.15 Distribution of slopefgsum6,t=0-3 and relationship to dose reductions/delays and therapy 
discontinuation. (A) Distribution of slopefgsum6,t=0-3 measurements observed in each treatment arm 
of CALGB 40502, where the numbers above the bars represent the number of patients with a 
given slopefgsum6,t=0-3 measurement. Median slopefgsum6,t=0-3 measurements are shown as red 
dotted vertical lines.  (B) Comparison of slopefgsum6,t=0-3 measurements between those who 
experience dose reduction/delay or discontinuation for sensory peripheral neuropathy (blue) and 
those who do not have any reported events (pink). The number of measurements in each boxplot 
are denoted on the x-axis. Differences between the two groups are significant in all three 
treatment arms and P values are shown in below plot (Mann-Whitney-Wilcoxon test). 
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Slopefgsum6,t=0-3 identified as early predictor for dose-limiting neuropathy 
Since each construct of fgsum4 and fgsum6 scores were able to distinguish between patients with 
RDD for peripheral neuropathy, each were tested as a predictor in a conditional logistic 
regression stratified by treatment arm prediction of RDD status. For each construct, a model was 
trained with 75% of the data from the PRO cohort with complete information and subsequently a 
model AUCROC was calculated on the remaining 25%. Among the six constructs, slopefgsum6,t=0-3 
had the largest model AUCROC (0.675) and a prediction accuracy of 71.3% to predict RDD for 
sensory peripheral neuropathy (Table 4.2, Figure 4.16). Except for the slope constructs, using 
fgsum6 scores did not further improve the prediction compared with the corresponding variables 
using fgsum4 scores alone (Table 4.2). Since the slope construct using fgsum6 had a marginal 
improvement over slope construct using fgsum4, slopefgsum6,t=0-3 was selected as the best early 
predictor for the final PRO model. 
 
Table 4.2 Model AUCROC and prediction accuracy for each predictor analyzed for prediction of 
RDD using PRO cohort. 
Predictor No. Subjects† Test set AUCROC (95% CI) Accuracy (95% CI) 
AUCfgsum4,t=0-3 719 179 0.655 (0.555-0.755) 0.743 (0.673-0.805) 
AUCfgsum6,t=0-3 719 179 0.653 (0.554-0.753) 0.760 (0.690-0.820) 
slopefgsum4,t=0-3 703 175 0.667 (0.568-0.765) 0.713 (0.636-0.783) 
slopefgsum6,t=0-3 703 175 0.675 (0.578-0.772) 0.720 (0.643-0.788) 
fgsum4t=3 629 156 0.592 (0.484-0.699) 0.737 (0.665-0.801) 
fgsum6t=3 629 156 0.584 (0.477-0.692) 0.737 (0.665-0.801) 
†Total number of subjects in PRO cohort with available predictor information 
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Figure 4.16 Receiver operating characteristic (ROC) curves for each construct using the PRO 
cohort. ROC curve illustrates the performance ability of the models with each construct to 
distinguish between RDD status for peripheral neuropathy. The model AUCROC for each model 
is shown with 95% confidence intervals. Slopefgsum6,t=0-3 has the largest model AUCROC (0.675) 
to predict RDDs for sensory peripheral neuropathy. 
 
Prediction analysis 
A final PRO prediction model for RDD was generated on PRO EUR cohort (n = 382) using 
slopefgsum6,t=0-3 as the primary predictor within the framework of a conditional logistic regression, 
stratifying for treatment arm. To evaluate if any patient characteristics are critical to dose 
reductions/delays or therapy discontinuations for sensory peripheral neuropathy, a stepwise 
backwards regression was performed on clinical features, including self-reported race/ethnicity, 
age, hormone receptor status, bevacizumab therapy, visceral metastases, diabetic status, prior 
taxane status, and body surface area; no clinical features remained in the model. The final PRO 
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prediction model was validated on the PRO non-EUR cohort with a model AUCROC of 0.652 
(95% CI: 0.550-0.753) (Figure 4.17).  
 To assess if the addition of SNPs would improve the prediction model, a 10-fold cross-
validation was performed to generate a prediction model with slopefgsum6,t=0-3 and SNPs using the 
PRO EUR cohort (Figure 4.2). Ten GWAS were performed on each training set to identify SNPs 
that associate with RDD for sensory neuropathy. Among the ten analyses, no SNP association 
reached genome-wide significance (P < 5E-08). However, a total of 103 unique SNPs reached P 
< 1E-04 across all GWAS; four SNPs (rs686865, rs12751148, rs7953698, rs8134611) remained 
in at least 50% of initial models after stepwise backwards regression with training set (Figure 
4.18). These SNPs were added into the final PRO genetic model and applied to the PRO non-
EUR cohort. The resulting model AUCROC which included both slopefgsum6,t=0-3 and SNP features 
is 0.607 (95% CI: 0.502-0.711), showing no improvement compared to PRO prediction model 
(Figure 4.17).  
 
Figure 4.17 ROC curve for prediction analysis using PRO non-EUR cohort with final PRO 
prediction models with and without genetics. ROC curve illustrates the performance ability of 
model PRO information alone (A) and with the addition of four SNPs (rs686865, rs12751148, 
rs7953698, rs8134611) (B) to predict RDD status for peripheral neuropathy.  
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Figure 4.18 Number of times SNPs selected from stepwise backward regression. Each dot 
represents a SNP from the 115 unique SNPs with association of P < 10-4 across ten GWAS. Only 
four SNPs (rs686865, rs12751148, rs7953698, rs8134611) were selected at least 50% of the 
models. 
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DISCUSSION 
Patient-reported outcomes of CIPN are an increasingly recognized tool to comprehensively 
monitor, evaluate, and manage CIPN progression during treatment. However, there is no current 
standard to implement the use of PRO into clinical decisions and there remains a need to develop 
an effective and simple strategy for prevention of dose-limiting neuropathy events. Previous 
studies have shown the specific reliability and validity of the sensory subscale of FACT/GOG-
Ntx to assess neuropathy symptoms15–20. In this study, we validate that patient-reported scores 
from the FACT/GOG-Ntx subscale (fgsum4 and fgsum6) distinguished between those who 
experience clinician-reported sensory neuropathy events and those who had no reported events 
regardless of chemotherapy regimen as early as the first treatment cycle. Furthermore, we also 
validate the ability of FACT/GOG-Ntx subscale to capture patient neurotoxicity profiles over 
time, where CIPN cases often report increases in fgsum4 and fgsum6 scores prior to the time of a 
clinician-reported neuropathy event. Because of this, six different constructs of fgsum4 and 
fgsum6 scores were created to investigate if CIPN symptoms at the latest time considered (score 
at cycle 3), cumulative symptom exposure (score AUC until cycle 3), or symptom progression 
(slope of scores until cycle 3) were predictors for dose reductions/delays or therapy 
discontinuation. All six constructs were able to show differences between patients with and 
without reported RDD for sensory peripheral neuropathy (Table 4.2), where higher scores, score 
AUCs, and slopes were observed in the group with reported RDD for sensory neuropathy 
regardless of treatment arm. Among the six constructs, slopes using both fgsum4 and fgsum6 
scores predicted RDD status with the highest AUCROC values (0.667 and 0.675, respectively). 
Interestingly, although slopefgsum6,t=0-3 showed the highest predictive ability among all six 
constructs, the addition of the two dysfunctional items to summed scores did not drastically 
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improve the predictive accuracy, which is in accordance with Huang et al. 200715 who reported 
that the four-item sensory scale alone efficiently captures clinically relevant neuropathy. It is 
possible that the PRO prediction model may perform similarly with only the four-item sensory 
scale, which can be further investigated with additional independent validation cohorts.  
While the PRO prediction model using slopefgsum4,t=0-3 showed some predictive value 
(AUCROC: 0.652 (0.550-0.753)), we also asked whether the addition of genome-wide data 
improves the prediction of RDD for sensory neuropathy. A 10-fold cross validated analysis 
(Figure 4.2) was performed in the PRO EUR cohort to build a PRO genetic prediction model 
using slopefgsum6,t=0-3 and four selected SNPs (rs686865, rs12751148, rs7953698, rs8134611). In 
comparison to the model with PRO information alone, there was no improvement with the 
addition of genetic covariates to the model (AUCROC: 0.607 (0.502-0.711)). Due to sample size 
constraints, it is possible these SNPs are not predictive in a multi-ethnic population as they were 
initially discovered in a genetically estimated European population. Future work focused on the 
inclusion of more appropriately sized multi-ethnic populations will likely identify SNPs that may 
improve the prediction model. Alternatively, the use of other regression methods aimed at 
incorporating genome-wide data without a high risk of overfitting may also warrant better 
prediction models. Rashkin et al. 201913 applied the elastic net regularization in development of 
a prediction model for progression-free survival using both clinical features and SNPs in 
CALGB 40502. While this study employed a similar 10-fold cross validated analysis, the elastic 
net regression or other penalized regression methods can be applied to improve SNP selection 
and reduce overfitting.  
While the focus of the study was to develop a predictive model with multiple SNPs that 
collectively show predictive ability, the analysis revealed some potentially biologically relevant 
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genes (Table 4.3) annotated to the selected SNPs. rs8134611 is a SNP located 27 kb 5’ of 
DSCAM, a gene encoding a cell adhesion molecule and netrin-1 receptor shown to play a critical 
role in regulating axonal growth and guidance during neural development21 that may be 
regulated directly by sphingolipid signaling22. Mutations in DSCAM in vivo have shown to 
impair peripheral signals to spinal circuits and result in sensorimotor controls23,24.  The SNP 
rs7953698 which lies 61 kb 5’ of C12orf67 has been shown to be an eQTL for expression of 
BCAT125, a gene encoding an isoform for BCAT enzyme that functions in glutamate metabolism. 
Interestingly, gabapentin, a commonly prescribed anticonvulsant drug for diabetic neuropathy 
and CIPN, competitively inhibits BCAT1/2 to slow glutamate production and reduce neuropathic 
pain. This notion may suggest that the protective effect of the SNP may be acting similarly to 
reduce glutamate levels. The SNP rs12751148 lies within the intronic region of TGFBR3, 
encoding betaglycan or formerly known as transforming growth factor (TGF)-b type III receptor. 
Betaglycan is an accessory receptor that lacks a TGF-b signaling domain but functions primarily 
to regulate TGFb signaling via binding and reserving ligands for TGFb type I/II receptors26. 
Interestingly, stimulating TGFb signaling has been shown to attenuate chronic nerve injury and 
neuropathic pain27–29. Although TGFBR3 may be an interesting genetic target, it is unclear how 
variations in betaglycan might affect TGF-b signaling under chemotherapy exposure and 
warrants further investigation. Lastly, the SNP rs686865 is located in a gene desert with the 
nearest gene 605 kb away from the 3’ end of PLOD2, a gene encoding a member of a protein 
family responsible for stabilizing collagen molecules in the extracellular matrix30 that has been 
implicated in RhoA-mediated axonal cytoskeletal arrangements in primary dorsal root ganglia31. 
Functional investigation of these genes may point to novel mechanisms of CIPN and aid in 
understanding the genetic factors involved in development of CIPN symptoms. 
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Table 4.3 Effect of clinical and genetic features for risk of dose reductions/delays and therapy 
discontinuation using the PRO GWAS cohort (N=502). 
Variable Chr Gene† MAF‡ b SE P 
Slopefgsum6,t=0-3 – – – 0.368 0.060 1.05E-09 
rs8134611 21 DSCAM 0.46 / 0.25 0.431 0.145 4.86E-06 
rs7953698 12 C12orf67 0.16 / 0.06 -0.889 0.226 8.22E-05 
rs12751148 1 TGFBR3 0.35 / 0.10 -0.767 0.168 0.00302 
rs686865 3 PLOD2 0.41 / 0.54 -0.433 0.150 0.00395 
†Nearest gene using refGene annotation 
‡MAF denoted in PRO EUR / Non-EUR cohorts 
 
While other items in the FACT/GOG-Ntx subscale were not investigated in this study, 
motor and hearing neuropathy items may improve predictive ability when incorporating a wider 
cohort set treated with other chemotherapy regimens. For example, platinum-containing 
chemotherapy regimens often cause tinnitus and/or hearing loss while vincristine-treated patients 
can often present with gait issues. Furthermore, our study focused primarily on describing 
patient-reported neuropathic experiences as an alternative to NCI-CTCAE reporting, although a 
multi-component assessment based on both clinician-based criteria and patient-reported 
questionnaires may be more suitable to fully describe and predict CIPN symptoms. As more 
comprehensive studies incorporate the collection of PRO information to monitor CIPN, we will 
begin to more extensively investigate which early PRO information is most informative and how 
they can be appropriately used to predict dose-limiting neuropathy events across chemotherapy 
regimens.  
Overall in this study, we have identified slopefgsum6,t=0-3 as an early predictor of dose 
modifications or therapy discontinuation for sensory peripheral neuropathy in both PRO EUR 
and non-EUR cohorts, where increasing slopefgsum6,t=0-3 result in higher risk of dose-limiting 
neuropathy events. Consistent with our findings, a recent study32 using early patient-reported 
outcomes from CALGB 40502 data also demonstrated the predictive accuracy for high 
neuropathy scores at treatment cycle 6, which may be useful for preventative dose-adjustments. 
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While more complex phenotyping with early patient-reported outcomes may result in better 
prediction, our study focused on the need to phenotype and test simple constructs of early PRO 
measures that require minimal training and use for easy adoption into the clinical trial and 
clinical practice33.  Validation in independent multi-ethnic cohorts of slopefgsum6,t=0-3 is critical to 
translate our findings into clinical settings and identify a more comprehensive predictive 
signature that include germline variations. With the growing advances of technology in 
healthcare, there will be more opportunities and innovative techniques to continually monitor 
cancer survivorship enriched with large-scale data directly from patients. One recent study has 
demonstrated the use of wearable technologies to quantify balance and gait difficulties after 
chemotherapy, showing cancer patients with CIPN suffered from issues with ankle stability and 
slower stride velocity34, which likely contribute to increased risk of secondary mobility 
complications post-treatment. Future studies aimed at the use of innovative technologies and 
methods to appropriately monitor and control CIPN early holds promise for clinical application 
of patient-reported alongside clinician-based data, novel preventative strategies against CIPN 
including early screening methods for patient susceptibility to severe neuropathy, and improved 
clinical decisions that maximize chemotherapy benefit while limiting development of CIPN. 
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CHAPTER 5: Conclusions and Perspectives 
Summary 
Cytotoxic chemotherapies are commonly prescribed first-line treatments for various solid tumors 
that target and eradicate rapidly dividing cells. While clinically efficacious, these drugs are often 
accompanied by significant toxicities. One common dose-limiting toxicity of antineoplastic 
drugs is sensory peripheral neuropathy (PN), which can cause debilitating pain and abnormal 
sensory perception that persist for years1–4. Although there are known clinical features for risk of 
developing chemotherapy-induced peripheral neuropathy (CIPN), these factors still do not 
account for the observed interindividual variation in onset and severity of CIPN5. From 
functional mechanistic investigations in animal and in vitro models of CIPN, there is evidence to 
suggest that key genetic drivers may explain the initiation and development of CIPN6. Recent 
reverse translational studies are aimed at identifying these genetic networks underlying CIPN by 
investigating significant genetic variation among patients with and without reported CIPN and 
mechanistically studying how these drivers elicit chemotherapy-stimulated peripheral nerve 
degeneration. The research described in this dissertation explores the application of 
pharmacogenetic approaches to understand patient susceptibility and the underlying mechanisms 
contributing to microtubule-targeting agent (MTA)-induced PN. Alongside revealing novel 
insights to the pathophysiology of this complex dose-limiting toxicity, these efforts using 
human-level data are aimed at identifying actionable genomic targets that can directly translate 
into development of effective therapeutic strategies to prevent and treat CIPN.  
A meta-analysis of genome-wide association studies (GWAS) using genotyping array 
data in breast cancer patients treated with microtubule-targeting agents (CALGB 40101 and 
CALGB 40502) was conducted to identify novel genes associated with risk of developing MTA-
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induced PN (Chapter 2). SNP associations of cumulative dose to first instance of grade 2 or 
higher MTA-induced PN were tested. Among the associations based on P values, SNPs within a 
predicted regulatory region near S1PR1 were the highest-ranked associations. Patients harboring 
genetic variants in a predicted regulatory region downstream of S1PR1 were observed with 
higher cumulative incidence of peripheral neuropathy events during chemotherapy. Using human 
sensory neurons derived from induced pluripotent stem cells, we show that pharmacologically 
inhibiting sphingosine-1-phosphate receptor signaling attenuated paclitaxel-induced neuronal 
damage. This work provides further evidence to support previous implications of sphingosine-1-
phosphate receptor signaling in animal models of CIPN. Other top associations in the meta-
analysis further validated intronic SNPs of FGD4, a causal Charcot-Marie-Tooth disease gene 
that was initially highlighted in a previous GWAS of CALGB 40101, and implicated SNPs near 
CX3CL1, an inflammatory signaling gene suggested to be involved in paclitaxel-stimulated 
neuroinflammatory responses. Together, these findings warrant additional studies to investigate 
their exact mechanistic functions in the pathogenesis of CIPN. 
Alongside the meta-analysis, a discovery-based sequencing study was performed to 
determine whether rare or less common variation plays a significant role in MTA-induced PN 
(Chapter 3). Whole exomes and candidate gene regulatory regions were sequenced in MTA-
treated breast cancer patients of CALGB 40502. Gene-based associations of cumulative dose to 
first instance of grade 2 or higher MTA-induced PN were completed, aggregating effects of rare 
or low-frequency variants either in exomes across the genome or in targeted regulatory regions 
of candidate genes. Although there were no significant gene associations, our exploratory 
analyses did reveal additional genes involved in actin cytoskeletal reorganization (SHC4, 
TRIOBP, ACTG1) and impairment in sensory neuronal excitability (PEAR1). Additional 
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genome-wide association and functional studies on these genes are critical to validate their role 
in patient susceptibility of significant MTA-induced PN, and may lead to novel drug targets 
against CIPN. 
Collectively with other genome-wide studies on CIPN, there is emerging evidence that 
dysregulation of the actin cytoskeleton is a critical event in mechanistic development of 
chemotherapy-induced peripheral nerve degeneration. While the distinct role of the cytoskeleton 
to maintain cell shape and initiate cell migration is shared among most non-neuronal cells, the 
cytoskeletal structure and function in peripheral neurons are distinct, largely in part due to their 
length and constant reinnervation into the epidermis. The axon of peripheral afferent neurons is 
mainly comprised of microtubule and intermediate filaments that span the sensory connection 
from the spinal cord to the dermis. Along the terminal ends, actin structures regulate a 
specialized region called the growth cone, which is responsible to initiate growth, guidance, and 
extension of axons. During the normal process of axon generation and extension, a balanced 
coordination among actin, intermediate filaments, and microtubules allow for proper 
microtubule- and actin-polymerization cued by internal and external signals7. The main 
biological switches that regulate actin dynamics within the cytoskeleton are Rho GTPases 
(Cdc42, Rac1, and RhoA)8, which function to signal the formation of specific actin structures. 
Many genome-wide studies on CIPN have implicated genetic variations in molecular regulators 
of Rho GTPase activity (Figure 5.1), and warrant further functional studies to understand how 
this imbalance is elicited by chemotherapy exposure and how it propagates into CIPN symptoms.  
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Figure 5.1 Proposed mechanisms of actin cytoskeletal genes implicated in CIPN. Genes 
identified from the analyses described in this dissertation are denoted in blue. 
 
While genome-wide studies are continually providing insight into the mechanisms of 
CIPN, there is still a need to utilize this information for early screening of at-risk patients for 
severe neuropathy events. Although NCI-CTCAE reporting for sensory peripheral neuropathy is 
the most commonly used assessment in clinical settings, patient-reported outcomes have been 
shown to be more sensitive to characterize onset and progression of CIPN9; however, there are 
no current standardized means of implementing patient-reported outcomes (PRO) into clinical 
decisions. The use of early patient-reported outcomes and genotyping array data was explored as 
a tool to predict dose modifications/delays or therapy cessation due to sensory neuropathy 
(Chapter 4). Patient-reported scores of sensory and dysfunctional neuropathy items in the 
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FACT/GOG-Ntx questionnaire reported were used to define and test early predictors of dose-
limiting neuropathy. All defined early PRO predictors (AUCfgsum4,t=0-3, AUCfgsum6,t=0-3, 
slopefgsum4,t=0-3, slopefgsum6,t=0-3, fgsum4t=3, fgsum6t=3) were validated to distinguish between 
patients with and without clinician-reported sensory neuropathy events as early as the first cycle 
across MTA treatment, where the slopefgsum6,t=0-3 showed the best predictive ability. Although the 
addition of genetics did not show an improvement in the prediction model using slopefgsum6,t=0-3, 
this study has set a foundation for future investigations into the use of patient-reported outcomes 
and genome-wide data to predict clinically significant toxicity events. Additional work is 
required to incorporate the use of genome-wide data into an actionable prediction model of 
CIPN, which will be aimed at innovating novel strategies to improve patient outcomes and post-
treatment quality of life. 
 
Challenges, perspectives and future directions 
The research described within this dissertation highlights a persistent challenge in 
pharmacogenetic studies of adverse drug reactions. Even with growing interest in genetic studies, 
it remains a challenge to collect large, appropriately-powered studies for discovery and 
replication genetic studies. Large-scale publicly accessible sources of genome-wide data (e.g. 
UK Biobank) are often limited by the lack of information captured on drug response and toxicity, 
especially when phenotype curation involves multiple layers of clinical information. As growing 
efforts to standardize tracking and sharing of ‘big data’ are ongoing, we will begin to expect 
larger numbers in pharmacogenetic studies and gain even more insights into genetic influences 
on drug response and toxicity. 
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As most clinical settings will consistently use the NCI-CTCAE grading scale, the primary 
peripheral neuropathy phenotype used in these genetic studies stem from this reporting criteria; 
however, these criteria are known to encompass variation in interindividual grade interpretation10 
and can be reported differently among various protocols. A more comprehensive avenue to 
collect neuropathy data should focus on the incorporation of patient-reported outcomes (PROs) 
and clinician-based assessments. While CALGB 40502 captured both patient-reported and 
clinician-reported neuropathy data, the collection of both set of data types are not common 
practice and rarely continue to follow patients after therapy is completed. With the new wave of 
app-based technology, these outcomes will be more readily collected before, during, and after 
treatments and accessible for clinical and research implementation. The PRO characterization 
and prediction study was motivated to start these investigations and create simple and effective 
ways to utilize these data for early prevention strategies.  
The studies presented here focus on the impact of DNA sequence variation in individual 
risk of developing CIPN; however, there are other genetic mechanisms that may also affect 
CIPN risk not explored here. While we can infer regulatory genetic mechanisms based on 
prediction algorithms, it is critical to also consider chemotherapy-induced changes in epigenome, 
transcriptome, and proteome that can reveal novel insights on mechanisms underlying CIPN. 
Recent studies have shown roles in epigenetic modifications in peripheral nerve injury11–14 and 
transcriptomic changes associated with chemotherapy-induced neuropathy15–20. With the genetic 
advances in technology, future studies should use a multi-omics approach to study CIPN, which 
would lead to a better understanding of the overall drug-induced genomic changes that may be 
imperative to CIPN initiation and development. 
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Novel functional in vitro models of CIPN are emerging that more closely resemble that of 
human sensory neurons. These functional studies are crucial to validate the consequences of 
identified genetic variation within target tissues and translate them back to patient predisposition. 
While the mechanistic investigation using human iPSC-derived sensory neurons presented in 
Chapter 2 was focused on neuron-specific responses to chemotherapy exposure, we did not 
investigate the cross talk between neurons and non-neuronal supporting cells. There has been 
increasing evidence that satellite glial cells21–23 and Schwann cells24 may be contributing to 
CIPN similarly to the neuron itself, although it is not yet clear which are primary responses to 
direct chemotherapy stimulation or secondary responses to repair neuron damage initially present 
from chemotherapy exposure. Future studies on these newer in vitro model systems should focus 
on incorporating co-culture systems to investigate these potential mechanisms of CIPN. While 
these systems are imperative for mechanistic studies, other future work should also place 
attention on utilization of patient iPSC-derived sensory neurons as a means to directly interrogate 
how patient-specific genomic variations cause CIPN predisposition and translate these findings 
into tailored treatments to mitigate patient CIPN symptoms.  
 
Conclusion 
This dissertation explores the use of a pharmacogenetic approach to identify novel genetic 
variations that potentially influence susceptibility of developing MTA-induced sensory 
peripheral neuropathy and further advance our understanding of the mechanisms underlying this 
toxicity. The findings presented support the hypothesis that the primary mechanism to 
chemotherapy-induced peripheral nerve damage may involve disruption of the actin 
cytoskeleton. Functional studies to investigate Rho GTPase signaling pathways are critical to 
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uncovering actionable genetic drivers, which will inform the development of novel drug 
strategies against CIPN. Additionally, this dissertation sets the foundation for the use of patient 
genetics and early symptom monitoring to predict severe neuropathy and inform clinical 
decisions to balance maximum chemotherapy benefit and mitigate drug adverse risk. The 
application of prediction modeling in CIPN contributes new methods to enable the translation of 
validated genomic targets into strategies to screen, predict, manage, and treat at-risk patients 
genetically susceptible to CIPN. 
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